



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁶ : C07D 239/84, 239/94, 239/95, 403/04, A61K 31/505, C07D 409/12, 405/12, 401/12, 403/12, G01N 33/50</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/50370 (43) International Publication Date: 12 November 1998 (12.11.98)</p>
<p>(21) International Application Number: PCT/US98/09060 (22) International Filing Date: 1 May 1998 (01.05.98) (30) Priority Data: 60/045,351 2 May 1997 (02.05.97) US 60/060,152 26 September 1997 (26.09.97) US (71) Applicant (for all designated States except US): SUGEN, INC. [US/US]; 351 Galveston Drive, Redwood City, CA 94063 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Peng, C. [US/US]; 827 Camino Ricardo, Moraga, CA 94556 (US). MCMA- HON, Gerald [US/US]; 1414 Greenwich Street, San Fran- cisco, CA 94109 (US). WEINBERGER, Heinz [DE/DE]; Am Holzweg 3, D-65843 Sulzbach (DE). KUTSCHER, Bernhard [DE/DE]; Stresenmannstrasse 9, D-63477 Maintal (DE). APP, Harald [US/US]; 630 27th Street, San Francisco, CA 94131 (US). (74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS</p> <p>(57) Abstract</p> <p>The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compounds and pharmaceutical compositions comprising these compounds.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DESCRIPTION

METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH QUINAZOLINE-BASED COMPOUNDS

BACKGROUND OF THE INVENTION

The following description of the background of the invention is provided to aid in understanding the invention but is not admitted to be prior art to the
5 invention.

Cellular signal transduction is a fundamental mechanism whereby external stimuli regulating diverse cellular processes are relayed to the interior of cells. One of the key biochemical mechanisms of signal
10 transduction involves the reversible phosphorylation of proteins, which enables regulation of the activity of mature proteins by altering their structure and function.

The best characterized protein kinases in
15 eukaryotes phosphorylate proteins on the alcohol moiety of serine, threonine, and tyrosine residues. These kinases largely fall into two groups, those specific for phosphorylating serine and threonine, and those specific for phosphorylating tyrosine. Some kinases, referred to
20 as "dual specificity" kinases, are able to phosphorylate on tyrosine as well as serine/threonine residues.

Protein kinases can also be characterized by their location within the cell. Some kinases are

transmembrane receptor proteins, having extracellular domains capable of binding ligands external to the cell membrane. Binding the ligands alters the receptor protein kinase's catalytic activity. Others are non-receptor proteins lacking a transmembrane domain. Non-receptor protein kinases can be found in a variety of cellular compartments from the inner-surface of the cell membrane to the nucleus.

Many kinases are involved in regulatory cascades where their substrates may include other kinases whose activities are regulated by their phosphorylation state. Ultimately the activity of a downstream effector is modulated by phosphorylation resulting from activation of such a pathway.

The serine/threonine kinase family includes members that regulate many steps of signaling cascades, including cascades controlling cell growth, migration, differentiation, gene expression, muscle contraction, glucose metabolism, cellular protein synthesis, and regulation of the cell cycle.

An example of a non-receptor protein kinase that phosphorylates protein targets on serine and threonine residues is RAF. RAF modulates the catalytic activity of other protein kinases, such as the protein kinase that phosphorylates and thereby activates mitogen activated protein kinase (MAPK). RAF itself is activated by the membrane anchored protein RAS, which in turn is activated in response to ligand activated tyrosine receptor protein kinases such as epidermal

growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR). The biological importance of RAF in controlling cellular events is underscored by the finding that altered forms of RAF have been associated with cancer in organisms. Evidence
5 for importance of RAF in malignancies is provided in Monia et al., 1996, *Nature Medicine* 2: 668, incorporated herein by reference in its entirety including all figures and tables.

In an effort to discover novel treatments for
10 cancer and other diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that inhibit the function of protein kinases. Some small organic molecules form a class of compounds that modulate the function of protein kinases. Examples
15 of molecules that have been reported to inhibit the function of protein kinases are bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642), vinylene-azaindole derivatives (PCT WO 94/14808), 1-cyclopropyl-4-pyridyl-quinolones (U.S. Patent No.
20 5,330,992), styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic
25 compounds (PCT WO 92/21660), and benzylphosphonic acid compounds (PCT WO 91/15495).

Compounds that can traverse cell membranes and are resistant to acid hydrolysis are potentially advantageous therapeutics as they can become highly bioavailable after being administered orally to patients. However, many of these protein kinase inhibitors only weakly inhibit the function of protein kinases. In addition, many inhibit a variety of protein kinases and will therefore cause multiple side-effects when utilized as therapeutics for diseases.

Despite the significant progress that has been made in developing compounds for the treatment of cancer, there remains a need in the art to identify the particular structures and substitution patterns that form the compounds capable of modulating the function of particular protein kinases.

SUMMARY OF THE INVENTION

The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods for preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to pharmaceutical compositions comprising compounds identified by methods of the invention.

I. Methods for Screening Compounds that Modulate Serine/Threonine Protein Kinase Function

The methods of the present invention provide means for modulating the function of both receptor and cytosolic serine/threonine protein kinases. These
5 methods provide means of modulating the enzymes both in vitro and in vivo. For in vitro applications, the methods of the invention relate in part to method of identifying compounds that modulate the function of serine/threonine protein kinases.

10 Thus, in a first aspect, the invention features a method of modulating the function of a serine/threonine protein kinase with a quinazoline-based compound. The quinazoline compound is substituted at the 5-position with an optionally substituted five-membered or six
15 membered aryl or heteroaryl ring. The method comprises contacting cells expressing the serine/threonine protein kinase with the compound.

The term "function" refers to the cellular role of a serine/threonine protein kinase. The serine/threonine
20 protein kinase family includes members that regulate many steps in signaling cascades, including cascades controlling cell growth, migration, differentiation, gene expression, muscle contraction, glucose metabolism, cellular protein synthesis, and regulation of the cell
25 cycle.

The term "modulates" refers to the ability of a compound to alter the function of a protein kinase. A modulator preferably activates the catalytic activity of

a protein kinase, more preferably activates or inhibits the catalytic activity of a protein kinase depending on the concentration of the compound exposed to the protein kinase, or most preferably inhibits the catalytic activity of a protein kinase.

5 The term "catalytic activity", in the context of the invention, defines the rate at which a protein kinase phosphorylates a substrate. Catalytic activity can be measured, for example, by determining the amount of a substrate converted to a product as a function of
10 time. Phosphorylation of a substrate occurs at the active-site of a protein kinase. The active-site is normally a cavity in which the substrate binds to the protein kinase and is phosphorylated.

 The term "substrate" as used herein refers to a
15 molecule phosphorylated by a serine/threonine protein kinase. The substrate is preferably a peptide and more preferably a protein. In relation to the protein kinase RAF, preferred substrates are MEK and the MEK substrate MAPK.

20 The term "activates" refers to increasing the cellular function of a protein kinase. The protein kinase function is preferably the interaction with a natural binding partner and most preferably catalytic activity.

25 The term "inhibit" refers to decreasing the cellular function of a protein kinase. The protein kinase function is preferably the interaction with a natural binding partner and most preferably catalytic

activity.

The term "modulates" also refers to altering the function of a protein kinase by increasing or decreasing the probability that a complex forms between a protein kinase and a natural binding partner. A modulator
5 preferably increases the probability that such a complex forms between the protein kinase and the natural binding partner, more preferably increases or decreases the probability that a complex forms between the protein kinase and the natural binding partner depending on the
10 concentration of the compound exposed to the protein kinase, and most preferably decreases the probability that a complex forms between the protein kinase and the natural binding partner.

The term "complex" refers to an assembly of at
15 least two molecules bound to one another. Signal transduction complexes often contain at least two protein molecules bound to one another. For instance, a protein tyrosine receptor protein kinase, GRB2, SOS, RAF, and RAS assemble to form a signal transduction
20 complex in response to a mitogenic ligand.

The term "natural binding partner" refers to polypeptides that bind to a protein kinase. Natural binding partners can play a role in propagating a signal in a protein kinase signal transduction process. A
25 change in the interaction between a protein kinase and a natural binding partner can manifest itself as an increased or decreased probability that the interaction forms, or an increased or decreased concentration of the

protein kinase/natural binding partner complex.

A protein kinase natural binding partner can bind to a protein kinase with high affinity. High affinity represents an equilibrium binding constant on the order of 10^{-6} M or less. In addition, a natural binding partner can also transiently interact with a protein kinase intracellular region and chemically modify it. Protein kinase natural binding partners are chosen from a group that includes, but is not limited to, SRC homology 2 (SH2) or 3 (SH3) domains, other phosphoryl tyrosine binding (PTB) domains, guanine nucleotide exchange factors, protein phosphatases, and other protein kinases. Methods of determining changes in interactions between protein kinases and their natural binding partners are readily available in the art.

The term "serine/threonine protein kinase" refers to an enzyme with an amino acid sequence with at least 10% amino acid identity to other enzymes that phosphorylate proteins on serine and threonine residues. A serine/threonine protein kinase catalyzes the addition of phosphate onto proteins on serine and threonine residues. Serine/threonine protein kinases can exist as membrane bound proteins or cytosolic proteins.

The term "monitoring" refers to observing the effect of adding the compound to the cells of the method. The effect can be manifested in a change in cell phenotype, cell proliferation, protein kinase catalytic activity, or in the interaction between a protein kinase and a natural binding partner.


The term "contacting" as used herein refers to mixing a solution comprising a quinazoline compound of the invention with a liquid medium bathing the cells of the methods. The solution comprising the compound may also comprise another component, such as

5 dimethylsulfoxide (DMSO), which facilitates the uptake of the quinazoline compound or compounds into the cells of the methods. The solution comprising the quinazoline compound may be added to the medium bathing the cells by utilizing a delivery apparatus, such as a pipet-based

10 device or syringe-based device.

The term "quinazoline-based compound" refers to a quinazoline organic compound substituted with chemical substituents. Quinazoline compounds are of the general structure:

15



The term "compound" refers to the compound or a pharmaceutically acceptable salt, ester, amide, prodrug, isomer, or metabolite, thereof.

20 The term "pharmaceutically acceptable salt" refers to a formulation of a compound that does not abrogate the biological activity and properties of the compound. Pharmaceutical salts can be obtained by reacting a compound of the invention with inorganic acids such as

25 hydrochloric acid, hydrobromic acid, sulfuric acid,

nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, *p*-toluenesulfonic acid, salicylic acid and the like.

The term "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs may be easier to administer than the parent drug in some situations. For example, the prodrug may be bioavailable by oral administration but the parent is not, or the prodrug may improve solubility to allow for intravenous administration.

The term "substituted", as used herein, refers to a quinazoline compound that is derivatized with a five-membered or six-membered aryl or heteroaryl ring.

The term "5-substituted" as used herein refers to a quinazoline compound substituted at position 5 of the ring as described above.

The term "five-membered ring" as used herein refers to a cyclic structure comprising an atom at each of the five vertices of the structure.

The term "six-membered ring" refers to a cyclic structure comprising an atom at each of the six vertices of the structure.

The term "aryl", in the context of the invention, refers to a five-membered or six-membered ring, where the pi electrons of the atoms at vertices in the ring overlap with one another. An example of an aryl ring is benzene with the structure C_6H_6 . The aryl moiety may be substituted, and typical aryl substituents include halogen, trihalomethyl, hydroxyl, -SH, -OH, -NO₂, amine,

thioether, cyano, alkoxy, alkyl, and amino moieties.

The term "heteroaryl", like the definition of "aryl" also relates to the overlapping pi electrons of the vertice atoms, except that one or more of the vertice carbon atoms in the five-membered or six-membered rings are replaced with nitrogen, oxygen, or sulfur atoms. Examples of heteroaryl moieties are furyl, thienyl, pyrrolyl, imidazolyl, indolyl, pyridinyl, thiadiazolyl, thiazolyl, piperazinyl, dibenzfuranyl, and dibenzthienyl rings. The heteroaryl rings of the invention may be optionally substituted with one or more functional groups which are attached commonly to such rings, such as, e.g., hydroxyl, bromo, fluoro, chloro, iodo, mercapto or thio, cyano, cyanoamido, alkylthio, heterocycle, aryl, heteroaryl, carboxyl, oxo, alkoxycarbonyl, alkyl, alkenyl, nitro, amino, alkoxyl, and amido moieties.

In a preferred embodiment, the invention relates to the method of modulating the function of a serine/threonine protein kinase, where the protein kinase is RAF.

The RAF protein kinase phosphorylates protein targets on serine or threonine residues. One such protein target is the protein kinase (MEK) that phosphorylates and consequently activates mitogen activated protein kinase (MAPK). RAF itself is activated by the membrane-bound guanine triphosphate hydrolyzing enzyme RAS in response to mitogen-stimulated receptor protein tyrosine kinases, such as epidermal

growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR).

The methods of the present invention can detect compounds that modulate the function of the RAF protein kinase in cells. RAF phosphorylates a protein kinase (MEK) which in turn phosphorylates mitogen-activated protein kinase (MAPK). Assays that monitor only the phosphorylation of MEK by RAF are not sensitive because the phosphorylation levels of MEK are not significant. To overcome this sensitivity dilemma, the phosphorylation of both MEK and MAPK are followed in the assays of the present invention. The MAPK phosphorylation signal amplifies the MEK phosphorylation signal and allows RAF-dependent phosphorylation to be followed in assays, such as enzyme-linked immunosorbant assays. In addition, the assay of the invention is performed in a high throughput format such that many compounds can be rapidly monitored in a short period of time.

In another aspect, the invention features a method for identifying compounds that modulate the function of serine/threonine protein kinases. The method comprises the steps of contacting cells expressing the serine/threonine protein kinase with said compound and monitoring an effect upon the cells.

The term "effect" describes a change or an absence of a change in cell phenotype or cell proliferation. "Effect" can also describe a change or an absence of a change in the catalytic activity of the protein kinase.

"Effect" can also describe a change or an absence of a change in an interaction between the protein kinase and a natural binding partner.

In a preferred embodiment of the invention relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases, where
5 the effect is a change or an absence of a change in cell phenotype.

The term "cell phenotype" refers to the outward appearance of a cell or tissue or the function of the cell or tissue. Examples of cell phenotype are cell
10 size (reduction or enlargement), cell proliferation (increased or decreased numbers of cells), cell differentiation (a change or absence of a change in cell shape), cell survival, apoptosis (cell death), or the
15 utilization of a metabolic nutrient (e.g., glucose uptake). Changes or the absence of changes in cell phenotype are readily measured by techniques known in the art.

In another preferred embodiment, the invention
20 relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases, where the effect is a change or an absence of a change in cell proliferation.

The term "cell proliferation" refers to the rate at
25 which a group of cells divides. The number of cells growing in a vessel can be quantified by a person skilled in the art when that person visually counts the number of cells in a defined volume using a common light

microscope. Alternatively, cell proliferation rates can be quantified by laboratory apparatuses that optically or conductively measure the density of cells in an appropriate medium.

5 In another preferred embodiment, the invention relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases, where the effect is a change or an absence of a change in the interaction between the serine/threonine protein kinase with a natural binding partner.

10 The term "interaction", in the context of the invention, describes a complex formed between a protein kinase intracellular region and a natural binding partner or compound. The term "interaction" can also extend to a complex formed between a compound of the
15 invention with intracellular regions and/or extracellular regions of the protein kinase under study. Although a cytosolic protein kinase will have no extracellular region, a receptor protein kinase will harbor both an extracellular and an intracellular
20 region.

The term "intracellular region" as used herein refers to the portion of a protein kinase which exists inside a cell. The term "extracellular region" as used herein refers to a portion of a protein kinase which
25 exists outside of the cell.

In a preferred embodiment, the invention relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases that further comprises the following steps: (a) lysing the cells to render a lysate comprising serine/threonine protein kinase; (b) adsorbing the serine/threonine protein kinase to an antibody; (c) incubating the adsorbed serine/threonine protein kinase with a substrate or substrates; and (d) adsorbing the substrate or substrates to a solid support or antibody. The step of monitoring the effect on the cells comprises measuring the phosphate concentration of the substrate or substrates.

The term "lysing" as used herein refers to a method of disrupting the integrity of a cell such that its interior contents are liberated. Cell lysis is accomplished by many techniques known to persons skilled in the art. The method is accomplished preferably by sonication or cell sheering techniques and more preferably by detergent techniques.

The term "antibody" as used herein refers to a protein molecule that specifically binds a protein kinase. An antibody preferably binds to one class of protein kinase and more preferably specifically binds to the RAF protein kinase.

The term "specifically binds" as used herein refers to an antibody that binds a protein kinase with higher affinity than another protein kinase or cellular protein. An antibody that specifically binds to a

protein kinase will bind a higher concentration of the specific protein kinase than any other protein kinase or cellular protein.

The term "adsorbing" as used herein refers to the binding of a molecule to the surface of an antibody or solid support. Examples of solid supports are
5 chemically modified cellulose, such as phosphocellulose, and nylon. Antibodies can be linked to solid supports using techniques well known to individuals of ordinary skill in the art. See, e.g., Harlo & Lane, *Antibodies, A Laboratory Manual*, 1989, Cold Spring Harbor
10 Laboratories.


The term "measuring the phosphate concentration" as used herein refers to techniques commonly known to persons of ordinary skill in the art. These techniques
15 can involve quantifying the concentration of phosphate concentrations within a substrate or determining relative amounts of phosphate within a substrate. These techniques can include adsorbing the substrate to a membrane and detecting the amount of phosphate within
20 the substrate by radioactive measurements.

In another preferred embodiment, the invention relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases that further comprises the following steps: (a)
25 lysing the cells to render a lysate comprising RAF; (b) adsorbing the RAF to an antibody; (c) incubating the adsorbed RAF with MEK and MAPK; and (d) adsorbing the MEK and MAPK to a solid support or antibody or


antibodies. The step of measuring the effect on the cells comprises monitoring the phosphate concentration of said MEK and MAPK.

In a preferred embodiment, the invention relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases
 5 quinazoline-based compound has a structure set forth in formula I, II, or III:


(I)



(II)



10 (III)



where

(a) Z is oxygen, NX_1 , or sulfur, where X_1 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

5 (b) n is 0, 1, 2, 3, or 4;

(c) A_1 , A_2 , A_3 , A_4 , A_5 , and A_6 are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur;

10 (d) R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_2X_3 , where X_2 and X_3 are

15 independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(iv) halogen and trihalomethyl;

(v) a ketone of formula $-CO-X_4$, where X_4

20 is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl moieties;

(vi) a carboxylic acid of formula $-(X_5)_n-COOH$ or ester of formula $-(X_6)_n-COO-X_7$, where X_5 , X_6 , and X_7 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1;

(vii) an alcohol of formula $(X_8)_n-OH$ or an

- alkoxy moiety of formula $-(X_8)_n-O-X_9$, where X_8 and X_9 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl ring moieties and where n is 0 or 1, and where the ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;
- (viii) $-NHCOX_{10}$, where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aryl or heteroaryl ring moieties, where the ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;
- (ix) $-SO_2NX_{11}X_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;
- (x) a five-membered or six-membered aryl or heteroaryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;
- (g) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, where the five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the

quinazoline ring;

(h) R_{11} and R_{12} are independently selected from the group consisting of

- (i) hydrogen;
- (ii) saturated or unsaturated alkyl; and
- 5 (iii) Z' is carbon, oxygen, sulfur, or nitrogen and R_{13} and R_{14} taken together form a five-membered or six-membered heteroaryl ring with Z' as a ring member.

The term "alkyl" refers to a straight-chain or
10 branched aliphatic hydrocarbon. The alkyl group is preferably 1 to 10 carbons, more preferably a lower alkyl of from 1 to 7 carbons, and most preferably 1 to 4 carbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl,
15 pentyl, hexyl and the like. The alkyl group may be substituted and some typical alkyl substituents include hydroxyl, cyano, alkoxy, oxygen, sulfur, nitroxy, halogen, trihalomethyl, $-N(CH_3)_2$, amino, and $-SH$.

The term "saturated alkyl" refers to an alkyl
20 moiety that does not contain any alkene or alkyne moieties. The alkyl moiety may be branched or non-branched.

The term "unsaturated alkyl" refers to an alkyl
moiety that contains at least one alkene or alkyne
25 moiety. The alkyl moiety may be branched or non-branched.

The term "aldehyde" refers to a chemical moiety with formula $-(R)_n-CHO$, where R is selected from the

group consisting of saturated or unsaturated alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1.

The term "ketone" refers to a chemical moiety with formula $-(R)_n-CO-R'$, where R and R' are selected from the group consisting of saturated or unsaturated alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1.

The term "carboxylic acid" refers to a chemical moiety with formula $-(R)_n-COOH$, where R is selected from the group consisting of saturated or unsaturated alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1.

The term "ester" refers to a chemical moiety with formula $-(R)_n-COOR'$, where R and R' are independently selected from the group consisting of saturated or unsaturated alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1.

The term "alkoxy moiety" refers to a chemical substituent of formula $-OR$, where R is hydrogen or a saturated or unsaturated alkyl moiety.

The term "sulfone" refers to a chemical moiety with formula $-SO_2-R$, where R is selected from the group consisting of saturated or unsaturated alkyl and five-membered or six-membered aryl or heteroaryl moieties.

The term "halogen" refers to an atom selected from the group consisting of fluorine, chlorine, bromine, and iodine.

In yet another preferred embodiment, the invention

relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases, where the quinazoline-based compound has a structure set forth in formula I, II, or III, where

- (a) Z is oxygen, NX_1 , or sulfur, where X_1 is
5 selected from the group consisting of hydrogen and saturated or unsaturated alkyl;
(b) n is 0, 1, or 2;
(c) A_1 , A_2 , A_3 , A_4 , A_5 , and A_6 are independently
selected from the group consisting of carbon, nitrogen,
10 oxygen, and sulfur;

(d) R_1 and R_2 are independently selected from the group consisting of



- (i) hydrogen;
15 (ii) saturated or unsaturated alkyl;
(iii) NX_2X_3 , where X_2 and X_3 are
independently selected from the group consisting of
hydrogen and saturated or unsaturated alkyl; and
(iv) halogen and trihalomethyl;
20 (v) five-membered or six-membered aryl
or heteroaryl ring moiety;

(e) R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} are
independently selected from the group consisting of

- (i) hydrogen;
25 (ii) saturated or unsaturated alkyl;
(iii) NX_4X_5 , where X_4 and X_5 are
independently selected from the group consisting of
hydrogen and saturated or unsaturated alkyl; and

- (iv) halogen and trihalomethyl;
- (v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine;
- (vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety;
- (f) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, where the five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the quinazoline ring;
- (g) R_{11} and R_{12} are independently selected from the group consisting of
- (i) hydrogen; and
- (ii) saturated or unsaturated alkyl; and
- (h) Z' is nitrogen, oxygen, or sulfur and R_{13} and R_{14} taken together form a five-membered or six-membered heteroaryl ring moiety with Z' as a ring member, where the ring is optionally substituted with one, two, or three alkyl, halogen, trihalomethyl, carboxylate, or ester moieties.

Another preferred embodiment of the invention relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases, where the quinazoline-based compound has the structure set forth in formula IV or V:



where

(a) Z is oxygen or sulfur;

(b) n is 0 or 1;

(c) R₁ and R₂ are independently selected from the
5 group consisting of

(i) hydrogen;

(ii) NX₁X₂, where X₁ and X₂ are

independently selected from the group consisting of
hydrogen and saturated or unsaturated alkyl;

10 (iii) benzyl;

(d) R₃, R₄, and R₅ are independently selected from
the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

15 (iii) NX₃X₄, where X₃ and X₄ are

independently selected from the group consisting of

hydrogen and saturated or unsaturated alkyl;

(e) R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

5 (iii) NX_5X_6 , where X_5 and X_6 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl;

(iv) halogen and trihalomethyl

(v) $C(X_7)_3$, where X_7 is selected from the
10 group consisting of fluorine, chlorine, bromine, and iodine; and


(vi) methoxy;

(f) R_{11} and R_{12} are hydrogen; and


(g) Z' is nitrogen and R_{13} and R_{14} taken together
15 form a five-membered heteroaryl ring.

In another preferred embodiment, the invention relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases, where the quinazoline-based compound has a
20 structure set forth in formula VI or VII:

(VI)



(VII)



where

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

(b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently
5 selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_4X_5 , where X_4 and X_5 are

independently selected from the group consisting of
10 hydrogen and saturated or unsaturated alkyl;


(iv) halogen;

(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and


15 (vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.

In yet another preferred embodiment, the invention
20 relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases, where the quinazoline-based compound has a structure set forth in formula VIII or IX:

(VIII)



(IX)



where

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

5 (b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_4X_5 , where X_4 and X_5 are

10 independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl;

(iv) halogen;


(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and
15 iodine; and

(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.

20 In another preferred embodiment, the invention

relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases, where the quinazoline-based compound has a structure set forth in formula X:

5 (X)



where

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

10 (b) R_3 , R_4 , R_5 , and R_6 are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_4X_5 , where X_4 and X_5 are

15 independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl;



(iv) halogen;

(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and
20 iodine; and





(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated

alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.









In another preferred embodiment, the invention relates to the method for identifying compounds that modulate the function of serine/threonine protein kinases, where the quinazoline-based compounds selected from the group consisting of compounds having the following formulas:








10



30



31



II. Methods of Preventing or Treating Abnormal Conditions

5

In another aspect, the invention features a method of preventing or treating an abnormal condition in an organism. The method comprises the step of administering a compound of the invention, as specified

herein by formula I, II, III, IV, V, VI, VII, VIII, IX or X, with any of the constraints provided herein, to an organism.

The term "organism" relates to any living entity comprising at least one cell. An organism can be as
5 simple as one eukaryotic cell or as complex as a mammal. In preferred embodiments, an organism refers to humans or mammals.

The term "preventing" refers to the method of the invention decreasing the probability, or eliminating the
10 possibility, that an organism contracts or develops the abnormal condition.

The term "treating" refers to the method of the invention having a therapeutic effect and at least partially alleviating or abrogating the abnormal
15 condition in the organism.

The term "therapeutic effect" refers to the inhibition of cell growth causing or contributing to an abnormal condition (e.g. cancer). The term "therapeutic effect" also refers to the inhibition of growth factors
20 causing or contributing to the abnormal condition. A therapeutic effect relieves to some extent one or more of the symptoms of the abnormal condition. In reference to the treatment of a cancer, a therapeutic effect refers to one or more of the following: (a) a reduction
25 in tumor size; (b) inhibition (i.e., slowing or stopping) tumor metastasis; (c) inhibition of tumor growth; and (d) relieving to some extent one or more of the symptoms associated with the abnormal condition.

Compounds demonstrating efficacy against leukemias can be identified as described herein, except that rather than inhibiting metastasis, the compounds may instead slow or decrease cell proliferation or cell growth.

The term "abnormal condition" refers to a function
5 in the cells or tissues of an organism that deviates from their normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation, or cell survival.

Aberrant cell proliferative conditions include
10 cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.

Aberrant differentiation conditions include, but are not limited to neurodegenerative disorders, slow
15 wound healing rates, and tissue grafting techniques.

Aberrant cell survival conditions relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis
20 pathways. Aberrations in the function of any one of the protein kinases could lead to cell immortality or premature cell death.

Cell proliferation, differentiation, and survival are phenomena simply measured by methods in the art.
25 These methods can involve observing the number of cells or the appearance of cells under a microscope with respect to time (for example, days).

The term "administering" relates broadly to the

provision to an organism and more specifically to a method of incorporating a compound into cells or tissues of an organism. The abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism.

5 Cells existing outside the organism can be maintained or grown in cell culture dishes. For cells harbored within the organism, many techniques exist in the art to administer compounds, including (but not limited to) oral, parenteral, dermal, injection, and aerosol
10 applications. For cells outside of the organism, multiple techniques exist in the art to administer the compounds, including (but not limited to) cell microinjection techniques, transformation techniques, and carrier techniques.

15 In another preferred embodiment, the invention relates to a method of preventing or treating an abnormal condition in an organism, where the organism is a mammal.

The term "mammal" refers preferably to such
20 organisms as mice, rats, rabbits, guinea pigs, and goats, more preferably to monkeys and apes, and most preferably to humans.

In another preferred embodiment, the invention relates to a method of preventing or treating an
25 abnormal condition in an organism, where the abnormal condition is cancer or a fibrotic disorder.

In yet another preferred embodiment, the invention relates to a method of preventing or treating an

abnormal condition in an organism, where the cancer is selected from the group consisting of lung cancer, ovarian cancer, breast cancer, brain cancer, intra-axial brain cancer, colon cancer, prostate cancer, Karposi's sarcoma, melanoma, and glioma.

5 In still another preferred embodiment, the invention relates to a method of preventing or treating an abnormal condition in an organism, where the method applies to an abnormal condition associated with an aberration in a signal transduction pathway
10 characterized by an interaction between a serine/threonine protein kinase and a natural binding partner.

 The term "signal transduction pathway" refers to the propagation of a signal. In general, an
15 extracellular signal is transmitted through the cell membrane to become an intracellular signal. This signal can then stimulate a cellular response. The term also encompasses signals that are propagated entirely within a cell. The polypeptide molecules involved in signal
20 transduction processes are typically receptor and non-receptor protein kinases, receptor and non-receptor protein phosphatases, nucleotide exchange factors, and transcription factors.

 The term "aberration", in conjunction with a signal
25 transduction process, refers to a protein kinase that is over- or under-expressed in an organism, mutated such that its catalytic activity is lower or higher than wild-type protein kinase activity, mutated such that it

can no longer interact with a natural binding partner, is no longer modified by another protein kinase or protein phosphatase, or no longer interacts with a natural binding partner.

5 The term "promoting or disrupting the abnormal interaction" refers to a method that can be accomplished by administering a compound of the invention to cells or tissues in an organism. A compound can promote an interaction between a protein kinase and natural binding partners by forming favorable interactions with multiple
10 atoms at the complex interface. Alternatively, a compound can inhibit an interaction between a protein kinase and natural binding partners by compromising favorable interactions formed between atoms at the complex interface.

15 In another preferred embodiment, the invention relates to a method of preventing or treating an abnormal condition in an organism, where the serine/threonine protein kinase is RAF.

20 III. Compounds and Pharmaceutical Compositions of the Invention

In another aspect, the invention features quinazoline compounds having structures set forth in formula I, II, III, IV, V, VI, VII, VIII, IX or X, with
25 any chemical substitutions and constraints described herein.

As described above, the term "compound" refers to the compound or a pharmaceutically acceptable salt,

ester, amide, prodrug, isomer, or metabolite, thereof.

In another aspect the invention features a quinazoline compound selected from the group consisting of A-3, A-6, A-8, A-10, A-11, A-12, A-13, A-14, A-15, A-16, A-17, A-18, and A-19.

5 In another aspect, the invention features a pharmaceutical composition comprising a compound of the invention, as specified herein, or its salt, and a physiologically acceptable carrier or diluent. The pharmaceutical composition may comprise a compound
10 having a structure of any one of formulas I, II, III, IV, V, VI, VII, VIII, IX, and X with any of the chemical moieties and constraints provided herein for each of these formulas.

The term "pharmaceutical composition" refers to a
15 mixture of an quinazoline compound of the invention with other chemical components, such as diluents or carriers. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art
20 including, but not limited to, oral, injection, aerosol, parenteral, and topical administration. Pharmaceutical compositions can also be obtained by reacting compounds with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric
25 acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

The term "physiologically acceptable" defines a carrier or diluent that does not abrogate the biological


activity and properties of the compound.

The term "carrier" defines a chemical compound that facilitates the incorporation of a compound into cells or tissues. For example dimethyl sulfoxide (DMSO) is a commonly utilized carrier as it facilitates the uptake of many organic compounds into the cells or tissues of an organism.

The term "diluent" defines chemical compounds diluted in water that will dissolve the compound of interest as well as stabilize the biologically active form of the compound. Salts dissolved in buffered solutions are utilized as diluents in the art. One commonly used buffered solution is phosphate buffered saline because it mimics the salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.


IV. Synthetic Methods of the Invention

In another aspect, the invention features a method for synthesizing a compound of the invention. The method comprises the steps of: (a) mixing a first reactant with a second reactant, where the first reactant has a structure of formula XI:




and where the second reactant has a structure of formula (XII) or (XIII):

(XII)



(XIII)



where

- 5 (a) Z is oxygen or sulfur;
- (b) n is 0, 1, 2, 3, or 4;
- (c) A₁, A₂, A₃, A₄, A₅, and A₆ are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur;
- 10 (d) R₁ and R₂ are independently selected from the group consisting of
 - (i) hydrogen;
 - (ii) saturated or unsaturated alkyl;
 - (iii) NX₂X₃, where X₂ and X₃ are
 - 15 independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and
 - (iv) halogen or trihalomethyl;
 - (v) five-membered or six-membered aryl or heteroaryl ring moiety;
- 20 (e) R₃, R₄, R₅, R₆, R₇, R₈, R₉, and R₁₀ are independently selected from the group consisting of:
 - (i) hydrogen, provided that at least one

of R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} is a non-hydrogen moiety if R_2 is $-NH_2$;

(ii) saturated or unsaturated alkyl, wherein said R_8 is not methyl when R_2 is $-NH_2$ and when $n = 1$;

5 (iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

10 (iv) halogen or trihalomethyl, wherein said R_8 is not chlorine or fluorine when R_2 is $-NH_2$ and when $n = 1$;

(v) a ketone of formula $-CO-X_4$, where X_4 is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl moieties;

15 (vi) a carboxylic acid of formula $-(X_5)_n-COOH$ or ester of formula $-(X_6)_n-COO-X_7$, where X_5 , X_6 , and X_7 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1;

20 (vii) an alcohol of formula $(X_8)_n-OH$ or an alkoxy moiety of formula $-(X_8)_n-O-X_9$, where X_8 and X_9 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl ring moieties and where n is 0 or 1, and wherein said ring moieties are optionally substituted with one or more substituents selected from the group

consisting of alkyl, halogen, trihalomethyl, carboxylate, or ester;

(viii) -NHCOX_{10} , where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aryl or heteroaryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, or ester;

(ix) $\text{-SO}_2\text{NX}_{11}\text{X}_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(x) a five-membered or six-membered aryl or heteroaryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, or ester moieties;

(f) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the quinazoline ring;

(g) R_{11} and R_{12} are independently selected from the group consisting of

- (i) hydrogen;
- (ii) saturated or unsaturated alkyl; and
- (b) collecting precipitate.


The term "mixing" as used herein refers to the process of adding at least two compounds together in one vessel. One compound may be added to the vessel and manipulated (*i.e.*, by heating and/or cooling) before adding another compound or compounds. A first compound
5 might be added to the vessel and mixed with a solvent before another compound or compounds are added. The mixture may be stirred either manually by a person skilled in the art or stirred by a mechanical device, such as a magnetic stirring apparatus.

10 The term "collecting precipitate" as used herein refers to separating solid material from a synthesis reaction of the invention from liquid solvent and soluble compounds. Many examples in the art are useful for collecting precipitate from chemical reactions. The
15 separation may be achieved, for example, by pouring a synthesis reaction of the invention over a filter and washing the solid material with fresh solvent. In addition, a solution may be added to the synthesis reaction before separation of the solid material from
20 the liquid. For example, the synthesis reaction may be diluted with water or a lower alcohol to increase the probability that particular compounds in the synthesis reaction precipitate.

In another aspect, the invention features a method
25 for synthesizing a compound of the invention, where the method comprises the steps of: (a) mixing a first reactant with a second reactant, where the first reactant has a structure of formula XIV:


43

(XIV)




and where the second reactant has a structure of formula XV or XVI:

5 (XV)



(XVI)



where

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

10 (b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently selected from the group consisting of

(i) hydrogen, provided that at least one of R_3 , R_4 , R_5 , R_6 , and R_7 is a non-hydrogen moiety if R_2 is $-NH_2$;

15 (ii) saturated or unsaturated alkyl, wherein said R_5 is not methyl when R_2 is $-NH_2$;

(iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

20 (iv) halogen, wherein said R_5 is not

chlorine or fluorine when R_2 is $-NH_2$;

(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and

(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety; and


(b) collecting precipitate.

In yet another aspect, the invention features a method for synthesizing a compound of the invention, where the method comprising the steps of:

(a) mixing a first reactant with a second reactant, where the first reactant has a structure of formula XIV:

15


(XIV)




and where the second reactant has a structure of formula XVII or XVIII:

20

(XVII)



(XVIII)



where

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

(b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently
5 selected from the group consisting of

(i) hydrogen, provided that at least one of R_3 , R_4 , R_5 , R_6 , and R_7 is a non-hydrogen moiety if R_2 is $-NH_2$;

(ii) saturated or unsaturated alkyl,
10 wherein said R_5 is not methyl when R_2 is $-NH_2$;

(iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

(iv) halogen, wherein said R_5 is not
15 chlorine or fluorine when R_2 is $-NH_2$;

(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and

(vi) OX_7 , where X_7 is selected from the
20 group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety; and

(b) collecting precipitate.

In a preferred embodiment, the invention relates to
25 the methods of synthesizing a compound of the invention, where the first reactant and the second reactant are mixed in one or more solvents selected from the group consisting of dimethyl sulfoxide, potassium tert-

butoxide, and sodium hydride.


In yet another preferred embodiment, the invention relates to the methods of synthesizing a compound of the invention, where the ZH moiety is isothiocyanate.

In another preferred embodiment, the invention
5 relates to the methods of synthesizing a compound of the invention, where the first reactant and the second reactant are mixed in dichloromethane.


In another aspect, the invention features a method
10 for synthesizing a compound of the invention, where the method comprises the steps of:

(a) mixing a first reactant with a second reactant, where the first reactant is guanidinium carbonate, and where the second reactant has the structure set forth in formula XIX or XX:

15 (XIX)



(XX)



where

(a) A_1 , A_2 , A_3 , A_4 , A_5 , and A_6 are independently selected from the group consisting of carbon, nitrogen,

oxygen, and sulfur;

(b) $R_3, R_4, R_5, R_6, R_7, R_8, R_9$, and R_{10} are independently selected from the group consisting of:

- (i) hydrogen, provided that at least one of $R_3, R_4, R_5, R_6, R_7, R_8, R_9$, and R_{10} is a non-hydrogen moiety if R_2 is $-NH_2$;
- (ii) saturated or unsaturated alkyl, wherein said R_8 is not methyl when R_2 is $-NH_2$ and when $n = 1$;
- (iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;
- (iv) halogen or trihalomethyl, wherein said R_8 is not chlorine or fluorine when R_2 is $-NH_2$ and when $n = 1$;
- (v) a ketone of formula $-CO-X_4$, where X_4 is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl moieties;
- (vi) a carboxylic acid of formula $-(X_5)_n-COOH$ or ester of formula $-(X_6)_n-COO-X_7$, where X_5, X_6 , and X_7 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1;
- (vii) an alcohol of formula $(X_8)_n-OH$ or an alkoxy moiety of formula $-(X_8)_n-O-X_9$, where X_8 and X_9 are independently selected from the group consisting

of alkyl and five-membered or six-membered aryl or heteroaryl ring moieties and where n is 0 or 1, and wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, or ester;

(viii) $-\text{NHCOX}_{10}$, where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aryl or heteroaryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, or ester;

(ix) $-\text{SO}_2\text{NX}_{11}\text{X}_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(x) a five-membered or six-membered aryl or heteroaryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, or ester moieties;

(c) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the quinazoline ring;

(d) R_{11} and R_{12} are independently selected from

the group consisting of

- (i) hydrogen;
- (ii) saturated or unsaturated alkyl;

and

- (b) collecting precipitate.

5 In a preferred embodiment, the invention relates to the methods for synthesizing a compound of the invention, where the first reactant and the second reactant are mixed in N,N-dimethylacetamide.

10 The summary of the invention described above is non-limiting and other features and advantages of the invention will be apparent from the following description of the preferred embodiments, and from the claims.

15 DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. In addition, the invention relates in part to methods for
20 identifying compounds that modulate the function of serine/threonine protein kinases. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF.

RAF is a non-receptor protein kinase that is
25 recruited to the cell membrane when it binds to activated RAS, a guanine triphosphate hydrolyzing enzyme. RAS is activated when an activated receptor protein tyrosine kinase, such as EGFR or PDGFR, bind to

an adaptor protein, GRB2, and a guanine nucleotide exchange factor, SOS. SOS removes guanine diphosphate from RAS, replaces it with guanine triphosphate, and thereby activates RAS. RAS then binds RAF and consequently activates RAF. RAF may then phosphorylate
5 other protein targets on serine and threonine residues, such as the kinase (MEK) that phosphorylates and consequently activates mitogen-activated protein kinase (MAPK). Thus, RAF serves as an intermediary controlling factor in mitogen-activated signal transduction.

10 Due to the important regulatory role of RAF in cells, modifications to the amino acid sequence of RAF can alter its function and consequently modify cellular behavior. RAF's role in cell proliferation is underscored by the observation that mutations to RAF's
15 amino acid sequence have been associated with tumors and cancers. Because the mutations to RAF that give rise to cancer in cells lead to RAF molecules that display unregulated catalytic activity, inhibitors of RAF may alleviate or even abrogate the cell proliferation that
20 leads to cancer in these cells.

Methods of the present invention can detect compounds that modulate the function of the protein kinase RAF in cells. RAF phosphorylates a protein kinase (MEK) which in turn phosphorylates mitogen-
25 activated protein kinase (MAPK). Assays that monitor only the phosphorylation of MEK by RAF are not sensitive because the phosphorylation levels of MEK are not significant. To overcome this sensitivity dilemma, the

phosphorylation of both MEK and MAPK are followed in the assays of the present invention. The MAPK phosphorylation signal amplifies the MEK phosphorylation signal and allows RAF-dependent phosphorylation to be followed in enzyme-linked immunosorbant assays. In addition, the assay of the invention is preferably performed in a high throughput format such that many compounds can be rapidly monitored in a short period of time.

The methods of the present invention have identified compounds that inhibit the function of the RAF protein kinase. These compounds are quinazoline-based derivatives. Although quinazoline-based derivatives have been tested for their ability to inhibit enzymes involved with nucleotide synthesis in bacteria, many of these compounds have not yet been significantly explored with respect to protein kinase inhibition.

Because RAF exhibits significant amino acid homology to other serine/threonine protein kinases, the quinazoline-based compounds of the invention may likely inhibit serine/threonine protein kinases other than RAF. Thus, the methods of the invention relate to serine/threonine protein kinases other than RAF, including receptor and non-receptor serine/threonine protein kinases.

The methods of the invention also pertain to other compounds that modulate RAF function in cells as the high throughput aspect of the methods allow a wide array

of molecules to be tested in a short period of time. Therefore, the methods of the invention can identify existing molecules not disclosed in the present invention that modulate RAF function.

Quinazoline compounds can be tested for their
5 ability to prevent and treat abnormal conditions, such as cancers, using the methods provided herein. Quinazoline compounds have been previously tested as antibacterial agents, since these compounds inhibit enzymes crucial to the survival of bacteria but not
10 critical to the survival of higher organisms. Quinazoline-based inhibitors of dihydrofolate reductase are described in Harris et al., 1990, *J. Med. Chem.* 33 (1):434-444. Quinazoline-based inhibitors of thymidylate synthetase are described in Webber et al.,
15 1993, *J. Med. Chem.* 36 (6):733-746 and Marsham et al., 1989, *J. Med. Chem.* 32 (3):569-575.

I. Biological Activity of Quinazoline-Based Compounds

Quinazoline-based compounds of the present
20 invention were tested for their ability to inhibit RAF protein kinase function. The biological assays and results of these inhibition studies are reported herein.

The methods used to measure quinazoline-based compound modulation of protein kinase function are similar to
25 those described in U.S. Application Serial No. 08/702,232, Tang et al., filed August 23, 1996, which is a continuation-in-part application of U.S. Application Serial No. 08/655,255 filed June 5, 1996, with respect

to the high throughput aspect of the method. The 08/702,232 application is incorporated herein by reference in its entirety, including any drawings.

5 II. Target Diseases to be Treated by Quinazoline-Based Compounds

 The methods, compounds, and pharmaceutical compositions described herein are designed to inhibit cell proliferative disorders by modulating the function of the RAF protein kinase. Proliferative disorders
10 result in unwanted cell proliferation of one or more subsets of cells in a multicellular organism resulting in harm to the organism. The methods, compounds, and pharmaceutical compositions described herein may also be useful for treating and preventing other disorders in
15 organisms, such as disorders related to premature cell death (*i.e.*, neurological diseases) or inflammation. These disorders may be a result of RAF molecules that function inappropriately or a result of RAF-related protein kinase molecules that function inappropriately.

20 Alterations in the function of the RAF protein kinase or protein kinases related to RAF can lead to enhanced or decreased cell proliferative conditions evident in certain diseases. Aberrant cell proliferative conditions include cancers, fibrotic
25 disorders, mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, restenosis, and inflammation.

 Fibrotic disorders relate to the abnormal formation

of the cellular extracellular matrix. An example of a fibrotic disorder is hepatic cirrhosis. Hepatic cirrhosis is characterized by an increased concentration of extracellular matrix constituents resulting in the formation of a hepatic scar. Hepatic cirrhosis can
5 cause diseases such as cirrhosis of the liver.

Mesangial cell proliferative disorders occur due to the abnormal proliferation of mesangial cells. Mesangial proliferative disorders include various human renal diseases, such as glomerulonephritis, diabetic
10 nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies.

Preferred types of cancers that may be treated by the methods and compounds of the invention are lung
15 cancer, ovarian cancer, breast cancer, brain cancer, intra-axial brain cancer, colon cancer, prostate cancer, sarcoma, Kaposi's sarcoma, melanoma, and glioma. Evidence that the compounds and methods of the invention can effectively be utilized to stem and reverse the
20 proliferation of cancer cells is provided herein by reference.

Angiogenic and vasculogenic disorders result from excess proliferation of blood vessels. Blood vessel proliferation is necessary in a variety of normal
25 physiological processes such as embryonic development, corpus luteum formation, wound healing and organ regeneration. However, blood vessel proliferation is also essential in cancer tumor development. Other

examples of blood vessel proliferative disorders include arthritis, where new capillary blood vessels invade the joint and destroy cartilage. In addition, blood vessel proliferative diseases include ocular diseases, such as diabetic retinopathy, where new capillaries in the
5 retina invade the vitreous, bleed and cause blindness. Conversely, disorders related to the shrinkage, contraction or closing of blood vessels, such as restenosis, are also implicated in adverse regulation of protein kinases.

10 Moreover, vasculogenesis and angiogenesis are associated with the growth of malignant solid tumors and metastasis. A vigorously growing cancer tumor requires a nutrient and oxygen rich blood supply to continue growing. As a consequence, an abnormally large number
15 of capillary blood vessels often grow in concert with the tumor and act as supply lines to the tumor. In addition to supplying nutrients to the tumor, the new blood vessels embedded in a tumor provide a gateway for tumor cells to enter the circulation and metastasize to
20 distant sites in the organism. Folkman, 1990, *J. Natl. Cancer Inst.* 82:4-6.

Inappropriate RAF activity can stimulate cell proliferative disorders. Molecules specifically designed to modulate the function of the RAF protein
25 kinase have been shown to inhibit cellular proliferation. Specifically, antisense nucleic acid molecules, which are designed to both bind to message RNA encoding the RAF protein kinase and block

translation from that message, effectively reversed transformation of A549 cells *in vitro*. Monia et al., 1996, *Nature Medicine* 2: 688, incorporated herein by reference in its entirety including all figures and tables. A549 cells are human malignant cells.

5 These RAF-targeted antisense studies provide evidence that the quinazoline molecules of the invention, which modulate the function of the RAF protein kinase, can stem, and likely reverse, the proliferation of malignant cells in an organism. These
10 quinazoline compounds can be tested in the *in vitro* methods provided herein by example. Furthermore, the quinazoline compounds may be tested for their effect upon tumor cells *in vivo* by the xenograft methods also provided herein by example.

15 There exist at least two ways in which inappropriate RAF activity can stimulate unwanted cell proliferation of a particular type of cells: (1) directly stimulating growth of the particular cell, or (2) increasing vascularization of a particular area,
20 such as tumor tissue, thereby facilitating growth of the tissue.

 The use of the present invention is facilitated by first identifying whether the cell proliferation disorder is RAF driven. Once such disorders are
25 identified, patients suffering from such a disorder can be identified by analysis of their symptoms using procedures well known to physicians or veterinarians of ordinary skill in the art. Such patients can then be

treated as described herein.

Determining whether the cell proliferation disorder is RAF driven may be accomplished by first determining the level of RAF activity occurring in the cell or in a particular location in a patient's body. For example, in the case of cancer cells the level of one or more RAF activities may be compared for non-RAF driven cancers and RAF driven cancers. If the cancer cells have a higher level of RAF activity than RAF driven cancers, preferably equal to or greater than RAF driven cancers, then they are candidates for treatment using the described RAF-modulating methods and compounds of the invention.

In the case of cell proliferative disorders arising due to unwanted proliferation of non-cancer cells, the level of RAF activity is compared to that level occurring in the general population (e.g., the average level occurring in the general population of people or animals excluding those people or animals suffering from a cell proliferative disorder). If the unwanted cell proliferation disorder is characterized by a higher RAF level then occurring in the general population then the disorder is a candidate for treatment using the described RAF modulating methods and compounds of the invention.

III. Pharmaceutical Compositions and Administration of Quinazoline-Based Compounds

Methods of preparing pharmaceutical formulations of the compounds, methods of determining the amounts of compounds to be administered to a patient, and modes of administering compounds to an organism are disclosed in 5 U.S. Application Serial No. 08/702,282, filed August 23, 1996 and International patent publication number WO 96/22976, published August 1, 1996 both of which are incorporated herein by reference in their entirety, 10 including any drawings. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can be easily adapted to it.

EXAMPLES

15 The examples below are non-limiting and are merely representative of various aspects and features of the present invention. The examples describe methods for synthesizing compounds of the invention and methods for measuring an effect of a compound on the function of the 20 RAF protein kinase.

The cells used in the methods are commercially available. The nucleic acid vectors harbored by the cells are also commercially available and the sequences of genes for the various protein kinases are readily 25 accessible in sequence data banks. Thus, a person of ordinary skill in the art can readily recreate the cell lines in a timely manner by combining the commercially available cells, the commercially available nucleic acid

vectors, and the protein kinase genes using techniques readily available to persons of ordinary skill in the art.

5 EXAMPLE 1: PROCEDURES FOR SYNTHESIZING QUINAZOLINE
 COMPOUNDS OF THE INVENTION

 The quinazoline compounds of the invention were synthesized using procedures A, B, C, D, and E, as described below. These procedures were carried out using the following conditions, techniques, and methods
10 for evaluation:

 (i) evaporations were carried out by rotary evaporation in vacuo;

 (ii) operations were carried out under an atmosphere of an inert gas such as nitrogen;

15 (iii) high performance liquid chromatography procedures (HPLC) were performed on Merck LiChrosorb RP-18 reversed-phase silica obtained from E. Merck, Darmstadt, Germany;

 (iv) yields are given for illustration only and are
20 not necessarily the maximum attainable;

 (v) melting points are uncorrected and were determined using a HWS Mainz SG 2000 digital melting point apparatus;

 (vi) the structures of all compounds of the formula
25 (I), (II), and (III) of this invention were confirmed by proton magnetic resonance spectroscopy on a Bruker AMX500-NMR spectrophotometer, by elemental microanalysis and, in certain cases, by mass spectroscopy;


(vii) the purity of the structures were performed by thin layer chromatography (TLC) using silica gel (Merck Silica Gel 60 F254) or by HPLC;

(viii) intermediates were not generally fully characterized; and

5 (ix) purity was assessed by thin layer chromatography (TLC) or by HPLC.

The following specific procedures were utilized to synthesize quinazoline compounds depicted by the figure and table below.

10



15

20

25

No.	R1	X	R2	R3
A-1	phenyl	O	NH ₂	NH ₂
A-2	phenyl	S	NH ₂	NH ₂
A-3	phenyl	S	H	NH ₂
A-4	4-methylphenyl	S	NH ₂	NH ₂
A-5	4-chlorophenyl	S	NH ₂	NH ₂
A-6	4-methoxyphenyl	O	NH ₂	NH ₂
A-7	4-fluorophenyl	O	NH ₂	NH ₂
A-8	4-t-butylphenyl	O	NH ₂	NH ₂
A-9	4-methylphenyl	O	NH ₂	NH ₂

5	A-10	3,4-dimethoxyphenyl	O	NH ₂	NH ₂
	A-11	3-(trifluoromethyl)phenyl	O	NH ₂	NH ₂
	A-12	phenyl	o	phenyl	NH ₂
	A-13	4-fluorophenyl	O	H	NH ₂
	A-14	3-dimethylaminophenyl	O	NH ₂	NH ₂
10	A-15	4-methoxyphenyl	O	H	NH ₂
	A-16	4-chlorobenzyl	O	NH ₂	NH ₂
	A-17	4-methylbenzyl	O	NH ₂	NH ₂
	A-18	4-(trifluoromethyl)-benzyl	O	NH ₂	NH ₂
	A-19	R1-X- = pyrrolidin-1-yl		NH ₂	NH ₂
15	A-20	2-fluorophenyl	O	NH ₂	NH ₂
	A-21	3-bromophenyl	O	NH ₂	NH ₂
	A-22	2-methoxyphenyl	O	NH ₂	NH ₂
	A-23	3-methoxyphenyl	O	NH ₂	NH ₂
	A-24	4-benzyloxyphenyl	O	NH ₂	NH ₂
20	A-25	3-dimethylaminopropyl	O	NH ₂	NH ₂
	A-26	3-dimethylaminophenyl	O	H	NH ₂
	A-27	pyrid-3-yl	O	H	NH ₂
	A-28	4-benzyloxyphenyl	O	H	NH ₂
	A-29	3,4-methylenedioxy-phenyl	O	H	NH ₂
20	A-30	methoxy	O	NH ₂	NH ₂
	A-31	R1 -X = pyrrol-1 -yl		NH ₂	NH ₂
	A-32	4-methoxyphenyl	O	H	phenyl-CONH

A-33	4-methoxyphenyl	O	H	3-bromophenyl-NHCONH
A-34	4-methoxyphenyl	O	H	3-methoxyphenyl-NHCONH
A-35	phenyl	N H	NH ₂	NH ₂
A-36	4-methoxyphenyl	O	NH ₂	acetyl-NH
A-37	4-hydroxyphenyl	O	H	NH ₂
A-38	4-hydroxyphenyl	O	NH ₂	NH ₂

Procedure A - Method for the reaction of 2,4-diamino-5-fluoroquinazoline with sodium phenolates and sodium thiophenolates.

2,4-Diamino-5-fluoroquinazoline was prepared from 2,6-difluorobenzonitrile (Lancaster Synthesis, Acros Organics) according to the published method (J. Heterocyclic Chem. 25:1173 (1988)).

Dimethyl sulfoxide and sodium hydride (80% dispersion in mineral oil) were added to a dry flask maintained under an inert atmosphere at room temperature. A solution of phenol (optionally substituted) or thiophenol (optionally substituted) in dimethylsulfoxide was added to the stirred reaction mixture, heated to 60°C for 30 minutes and allowed to

cool. 2,4-Diamino-5-fluoroquinazoline was added all at once as the solid and the reaction was heated to about 150°C for 2-3 hours. After cooling to room temperature the suspension was diluted with water and methanol or another lower alcohol, the solid collected by vacuum
5 filtration, washed, recrystallized from an alcohol, ethyl acetate or n-butyl acetate, and dried at 50°C under vacuum. In the cases where the the sodium phenolates or sodium thiophenolates are commercially available, (eg, sodium thiophenolate, Fluka), they may
10 be reacted directly with 2,4-diamino-5-fluoroquinazoline in dimethylsulfoxide.

The following compounds were obtained according to Procedure A.

- 15 A-2 2,4-Diamino-5-phenylthioquinazoline, m.p. 240-244°C.
A-6 2,4-Diamino-5-(4-methoxyphenoxy)quinazoline, m.p. 268-270°C.
A-9 2,4-Diamino-5-(4-methylphenoxy)quinazoline, m.p.
20 268-270°C.
A-11 2,4-Diamino-5-(3-trifluoromethylphenoxy)quinazoline, m.p. 280-284°C (dec).

25 Procedure B - Method for the reaction of 2,4-diamino-5-fluoroquinazoline with potassium phenolates.

To a stirred suspension of potassium tert-butoxide in dimethyl sulfoxide under an inert atmosphere was

added 1 equivalent of the desired phenol (optionally substituted). After hydrogen evolution had ceased 2,4-diamino-5-fluoroquinazoline was added all at once as the solid and the mixture heated to about 150°C for 2-3 hours. After cooling to room temperature the suspension
5 was diluted with water and methanol or another lower alcohol, the solid collected by vacuum filtration, washed, and dried at 50°C under vacuum.

The following compounds have been obtained according to this procedure.

10

A-8 2,4-Diamino-5-(4-tert-butylphenoxy)quinazoline,
m.p. 226-228°C.

A-10 2,4-Diamino-5-(3,4-dimethoxyphenoxy)quinazoline,
m.p. 301-302°C.

15 A-14 2,4-Diamino-5-(3-dimethylaminophenoxy)quinazoline,
m.p. 224-225°C (dec).

A-20 2,4-Diamino-5-(2-fluorophenoxy)quinazoline, m.p.
301-303°C.

20 A-21 2,4-Diamino-5-(3-bromophenoxy)quinazoline, m.p.
292-295°C.

A-22 2,4-Diamino-5-(2-methoxyphenoxy)quinazoline, m.p.
208-209°C (dec).

A-23 2,4-Diamino-5-(3-methoxyphenoxy)quinazoline, m.p.
215-216°C (dec).

25 A-24 2,4-Diamino-5-(4-benzyloxyphenoxy)quinazoline, m.p.
175-177°C.

A-25 2,4-Diamino-5-(3-dimethylaminopropoxy)quinazoline,
m.p. 193-195°C

By substituting the appropriate phenol, alcohol or amine for the phenol or thiophenol in Procedure A or Procedure B the following compounds may be obtained.

- A-1 2,4-Diamino-5-phenoxyquinazoline.
- 5 A-7 2,4-Diamino-5-(4-fluorophenoxy)quinazoline.
- A-16 2,4-Diamino-5-(4-chlorobenzyloxy)quinazoline.
- A-17 2,4-Diamino-5-(4-methylbenzyloxy)quinazoline.
- A-18 2,4-Diamino-5-(4-trifluoromethylbenzyloxy)quinazoline.
- 10 A-19 2,4-Diamino-5-(pyrrolidin-1-yl)quinazoline.

Procedure C - Method for the reaction of 4-amino-5-fluoroquinazoline with potassium phenolates and sodium thiophenolates.

- 15 4-Amino-5-fluoroquinazoline was prepared from 2,6-difluorobenzonitrile (Lancaster Synthesis, Acros Organics) according to the published method (*J. Heterocyclic Chem.* 28: 1357 (1991)).

- For phenols, a solution of the phenol (optionally substituted) in dimethyl sulfoxide was added to a stirred mixture of potassium tert-butoxide in dimethyl sulfoxide at room temperature. After 15 minutes 4-amino-5-fluoroquinazoline was added all at once as the solid and the mixture was heated to about 50°C for 7 hours. After cooling to room temperature the suspension was diluted with water or water and a lower alcohol, the solid collected by vacuum filtration, washed, recrystallized from ethanol or n-butyl acetate, and
- 20
- 25

dried at 50°C under vacuum. For thiophenols, the sodium salt of the thiophenol was prepared as described in Procedure A and then reacted with 4-amino-5-fluoroquinazoline as described.

5 The following compounds were obtained according to Procedure C.

A-3 4-Amino-5-phenylthioquinazoline, m.p. 195-197°C.

A-15 4-Amino-5-(4-methoxyphenoxy)quinazoline, m.p. 192-195°C.

10 A-26 4-Amino-5-(3-dimethylaminophenoxy)quinazoline, m.p. 179-181°C.

A-27 4-Amino-5-(pyrid-3-oxy)quinazoline, m.p. 245-247°C.

A-28 4-Amino-5-(4-benzyloxyphenoxy)quinazoline, m.p. 170-171°C.

15 A-29 4-Amino-5-(3,4-methylenedioxyphenoxy)quinazoline, m.p. 201-203°C.

Procedure D - Method for the reaction of 6-substituted 2-fluorobenzonitriles with guanidine carbonate.

20 A mixture of 1 equivalent of 6-substituted 2-fluorobenzonitrile (Maybridge, Lancaster Synthesis) and 1.5 equivalents of guanidine carbonate in N,N-dimethylacetamide was heated under nitrogen at 140-150°C for 5-6 hours. The reaction mixture was allowed to cool
25 to room temperature overnight. The resulting suspension was diluted with water and methanol or another lower alcohol, and cooled to 4°C. The solid was collected by vacuum filtration, washed, recrystallized from n-butyl

acetate, and dried at 50°C under vacuum.

The following compounds were obtained according to Procedure D.

- 5 A-4 2,4-Diamino-5-(4-methylphenylthio)quinazoline, m.p. 206-207°C.
- A-5 2,4-Diamino-5-(4-chlorophenylthio)quinazoline, m.p. 220-224°C.
- A-30 2,4-Diamino-5-methoxyquinazoline, m.p. 199-202°C.
- 10 A-31 2,4-Diamino-5-(pyrrol-1-yl)quinazoline, m.p. 248-250°C.

In a synthetic process similar to that of Procedure D, the following compound was prepared.

- 15 A-12 4-Amino-2-phenyl-5-phenoxyquinazoline

A mixture of 2-fluoro-6--phenoxybenzonitrile (2.7 g, 13 mmol, Maybridge), benzamidine hydrochloride (3.0 g, 19 mmol, Aldrich) and sodium acetate (1.6 g, 19 mmol) in 60 mL of N,N-dimethylacetamide was heated at 150°C under nitrogen for 6.5 hours. After cooling to room temperature the reaction mixture was evaporated under reduced pressure. The product was suspended in a mixture of 20 mL of ethanol and 100 mL of water, and 10 mL of concentrated ammonium hydroxide was added. The solid was collected by vacuum filtration, washed with water, dried, recrystallized twice from 60 mL of 2-propanol at 4°C, and dried at 50°C under vacuum to give

0.5 g (12% yield) of 4-amino-2-phenyl-5-phenoxyquinazoline, m.p. 190-191°C.

A-13 4-Amino-5-(4-fluorophenoxy)quinazoline, m.p. 188-190°C.

5 A mixture of 2-fluoro-6-(4-fluorophenoxy) benzonitrile (2.5 g, 11 mmol, Maybridge) and formamidine acetate (2.3 g, 22 mmol, Aldrich) in 50 mL of N,N-dimethylacetamide was heated to 162°C under nitrogen for 9 hours. After cooling to room temperature the reaction
10 mixture was evaporated under reduced pressure. The product was suspended in 80 mL of cold water and the pH adjusted to 8.5 with concentrated ammonium hydroxide. After cooling the suspension overnight, the precipitate was collected by vacuum filtration, washed with water
15 (25 mL), dried and recrystallized from 30 mL of ethanol at 4°C. The precipitate was collected by vacuum filtration, washed with ethanol, and dried at 50°C to give 0.3 g (10.7 % yield) of 4-amino-5-(4-fluorophenoxy)quinazoline, M.P. 188-190°C.

20

Procedure E - Method for the reaction of 5-substituted 4-aminoquinazolines with aryl isocyanates.

To a stirred solution of 1 equivalent of the 5-substituted 4-aminoquinazoline in dichloromethane, 1.2-
25 1.3 equivalents of an aryl isocyanate (optionally substituted) was added at room temperature and stirring continued overnight. The precipitate was collected, washed with dichloromethane and dried at 50°C under

vacuum.

The following compounds were obtained according to Procedure E.

5 A-32 1-[5-(4-Methoxyphenoxy)quinazolin-4-yl]-3-phenylurea, m.p. 231-232°C.

A-33 1-[5-(4-Methoxyphenoxy)quinazolin-4-yl]-3-(3-bromophenyl)urea, m.p. 249-251°C.

10 A-34 1-[5-(4-Methoxyphenoxy)quinazolin-4-yl]-3-(3-methoxyphenyl)urea, m.p. 209-210°C.

The related compounds below were prepared by the following methods.

15 A-35 2,4-Diamino-5-anilinoquinazoline
Aniline (5.0 g, 50 mmol, Aldrich), sodium hydride (1.5 g, 50 mmol of an 80% dispersion in mineral oil) and 2,4-diamino-5-fluoroquinazoline (4.4 g, 25 mmol) in 80 mL of dimethyl sulfoxide were reacted as in Procedure A to give 0.3 g (4.8 % yield) of 2,4-diamino-5-anilinoquinazoline, m.p. 279-283°C (dec).

20 A-36 4-Acetamido-5-(4-methoxyphenoxy)quinazoline
To a stirred solution of 4-amino-5-(4-methoxyphenoxy)quinazoline (1.0 g, 3.7 mmol) in 30 mL of dichloromethane was added pyridine (0.3 g, 3.7 mmol) and acetic anhydride (0.38 g, 3.7 mmol) at room temperature and the mixture stirred for 4 days. After evaporation under reduced pressure, 30 mL of 2-propanol

was added, the mixture was cooled to 4°C, the solid was collected by vacuum filtration, washed, recrystallized from ethanol, and dried at 50°C under vacuum to give 0.5 g (45.4 % yield) of 4-acetamido-5-(4-methoxyphenoxy)quinazoline, m.p. 174-175 °C,

5

A-37 4-Amino-5-(4-hydroxyphenyloxy)quinazoline

4-Amino-5-(4-benzyloxyphenoxy)quinazoline (1.5 g, 4.4 mmol) was heated at 50-60°C under 5 atmospheres of hydrogen gas in the presence of 0.5 g of 10% palladium on carbon in 80 mL of N,N-dimethylacetamide. After 4 hours the reaction mixture was filtered through a fritted glass funnel containing silica gel, concentrated, dissolved in 80 mL of ethanol/water 4/1 (v/v) and allowed to crystallize at 4°C. The precipitate was collected by vacuum filtration, washed with ethanol and dried at 150°C under vacuum to give 0.3 g (27.3 % yield) of 4-amino-5-(4-hydroxyphenyl)quinazoline, m.p. 300-302°C (dec).

20 A-38 2,4-Diamino-5-(4-hydroxyphenyloxy)quinazoline

2,4-Diamino-5-(4-benzyloxyphenoxy)quinazoline (3.6 g, 10 mmol) was heated at 50-60°C under 4 atmospheres of hydrogen gas in the presence of 0.36 g of 10% palladium on carbon in 80 mL of N,N-dimethylacetamide. After 4 hours the reaction mixture was filtered through silica gel in a fritted glass funnel, concentrated, dissolved in 50 mL of 2-propanol and allowed to crystallize at 4°C. The precipitate was collected by vacuum filtration,

washed with 2-propanol and dried at 50°C under vacuum to give 2.3 g (85.2 % yield) of 2,4-diamino-5(4-hydroxyphenoxy)quinazoline, mp 330-341°C (dec).

5 EXAMPLE 2: ASSAY MEASURING PHOSPHORYLATING FUNCTION
 OF RAF

 The following assay reports the amount of RAF-catalyzed phosphorylation of its target protein MEK as well as MEK's target MAPK. The RAF gene sequence is described in Bonner et al., 1985, *Molec. Cell. Biol.* 5: 1400-1407, and is readily accessible in multiple gene
10 sequence data banks. Construction of the nucleic acid vector and cell lines utilized for this portion of the invention are fully described in Morrison et al., 1988, *Proc. Natl. Acad. Sci. USA* 85: 8855-8859.

15

Materials and Reagents

1. *Sf9* (*Spodoptera frugiperda*) cells; GIBCO-BRL, Gaithersburg, MD.
2. RIPA buffer: 20 mM Tris/HCl pH 7.4, 137 mM
20 NaCl, 10 % glycerol, 1 mM PMSF, 5 mg/L Aprotinin, 0.5 % Triton X-100;
3. Thioredoxin-MEK fusion protein (T-MEK): T-MEK expression and purification by affinity chromatography were performed according to the manufacturer's
25 procedures. Catalog# K 350-01 and R 350-40, Invitrogen Corp., San Diego, CA
4. His-MAPK (ERK 2); His-tagged MAPK was expressed in XL1 Blue cells transformed with pUC18

vector encoding His-MAPK. His-MAPK was purified by Ni-affinity chromatography. Cat# 27-4949-01, Pharmacia, Alameda, CA, as described herein.

5. Sheep anti mouse IgG: Jackson laboratories, West Grove, PA. Catalog, # 515-006-008, Lot# 28563

5 6. RAF-1 protein kinase specific antibody: URP2653 from UBI.

7. Coating buffer: PBS; phosphate buffered saline, GIBCO-BRL, Gaithersburg, MD

10 8. Wash buffer: TBST - 50 mM Tris/HCL pH 7.2, 150 mM NaCl, 0.1 % Triton X-100

9. Block buffer: TBST, 0.1 % ethanolamine pH 7.4

10. DMSO, Sigma, St. Louis, MO

11. Kinase buffer (KB): 20 mM Hepes/HCl pH 7.2, 150 mM NaCl, 0.1 % Triton X-100, 1 mM PMSF, 5 mg/L Aprotinin, 75 μ M sodium ortho vanadate, 0.5 mM DTT and 10 mM $MgCl_2$.

12. ATP mix: 100 mM $MgCl_2$, 300 μ M ATP, 10 μ Ci γ - ^{33}P ATP (Dupont-NEN)/mL.

13 Stop solution: 1 % phosphoric acid; Fisher, Pittsburgh, PA.

14. Wallac Cellulose Phosphate Filter mats; Wallac, Turku, Finland.

15. Filter wash solution: 1 % phosphoric acid, Fisher, Pittsburgh, PA.

16. Tomtec plate harvester, Wallac, Turku, Finland.

17. Wallac beta plate reader # 1205, Wallac, Turku, Finland.

18. NUNC 96-well V bottom polypropylene plates for compounds Applied Scientific Catalog # AS-72092.

Procedure

5 All of the following steps were conducted at room temperature unless specifically indicated.

1. ELISA plate coating: ELISA wells are coated with 100 μ L of Sheep anti mouse affinity purified antiserum (1 μ g/100 μ L coating buffer) over night at 4 $^{\circ}$ C. ELISA plates can be used for two weeks when stored
10 at 4 $^{\circ}$ C.

2. Invert the plate and remove liquid. Add 100 μ L of blocking solution and incubate for 30 min.

3. Remove blocking solution and wash four times with wash buffer. Pat the plate on a paper towel to
15 remove excess liquid.

4. Add 1 μ g of antibody specific for RAF-1 to each well and incubate for 1 hour. Wash as described in step 3.

5. Thaw lysates from RAS/RAF infected Sf9 cells
20 and dilute with TBST to 10 μ g/100 μ L. Add 10 μ g of diluted lysate to the wells and incubate for 1 hour. Shake the plate during incubation. Negative controls receive no lysate. Lysates from RAS/RAF infected Sf9 insect cells are prepared after cells are infected with
25 recombinant baculoviruses at a MOI of 5 for each virus, and harvested 48 hours later. The cells are washed once with PBS and lysed in RIPA buffer. Insoluble material

is removed by centrifugation (5 min at 10 000 x g). Aliquots of lysates are frozen in dry ice/ethanol and stored at - 80 °C until use.

6. Remove non-bound material and wash as outlined above (step 3).

5 7. Add 2 µg of T-MEK and 2 µg of His-MAEPK per well and adjust the volume to 40 µL with kinase buffer. Methods for purifying T-MEK and MAPK from cell extracts are provided herein by example.

10 8. Predilute compounds (stock solution 10 mg/mL DMSO) or extracts 20 fold in TBST plus 1% DMSO. Add 5 µL of the prediluted compounds/extracts to the wells described in step 6. Incubate for 20 min. Controls receive no drug.

15 9. Start the kinase reaction by addition of 5 µL ATP mix; Shake the plates on an ELISA plate shaker during incubation. 10. Stop the kinase reaction after 60 min by addition of 30 µL stop solution to each well.

20 11. Place the phosphocellulose mat and the ELISA plate in the Tomtec plate harvester. Harvest and wash the filter with the filter wash solution according to the manufacturers recommendation. Dry the filter mats. Seal the filter mats and place them in the holder. Insert the holder into radioactive detection apparatus
25 and quantify the radioactive phosphorous on the filter mats.

Alternatively, 40 µL aliquots from individual wells

of the assay plate can be transferred to the corresponding Positions on the phosphocellulose filter mat. After airdrying the filters, put the filters in a tray. Gently rock the tray, changing the wash solution at 15 min intervals for 1 hour. Air-dry the filter
5 mats. Seal the filter mats and place them in a holder suitable for measuring the radioactive phosphorous in the samples. Insert the holder into a detection device and quantify the radioactive phosphorous on the filter mats.

10 IC_{50} values were measured according to the protocol for quinazoline-based compounds in the RAF-1 ELISA assay. An IC_{50} value is the concentration of the quinazoline-based inhibitor required to decrease the maximum amount of phosphorylated target protein or cell
15 growth by 50%. The IC_{50} values measured in the RAF-1 phosphorylation assay are depicted in Table 1:

TABLE 1

Compound	IC ₅₀ (μM)
A-1	0.3
A-3	25.6
A-6	0.8
A-7	5.8
A-8	> 100
A-9	4.5
A-11	> 100
A-12	> 100
A-13	0.1
A-14	24.6
A-15	0.8
A-5	> 100
A-14	57
A-22	20
A-23	6.4
A-28	0.3
A-4	> 100

5

10

15

20

EXAMPLE 3: PURIFICATION OF MAPK AND MEK

The MAPK and MEK proteins are readily expressed in cells by subcloning a gene encoding these proteins into a commercially available vector that expresses the proteins with a poly-Histidine tag. Genes encoding these proteins are readily available from laboratories that normally work with these proteins or by cloning these genes from cells containing cDNA libraries. The libraries are readily commercially available and a person skilled in the art can readily design nucleic acid probes homologous to cDNA molecules encoding MEK or MAPK from the nucleic acid sequences of MEK and MAPK, available in multiple gene data bases such as Genbank. The cloning of a gene can be accomplished in a short time period using techniques currently available to persons skilled in the art.

Purification of the MEK and MAPK proteins from cell extracts can be accomplished using the following protocol, which is adapted from Robbins et al., 1993, *J. Biol. Chem.* 268: 5097-5106:

1. Lyse cells by sonication, osmotic stress, or French Press techniques readily available to persons skilled in the art. An appropriate sonication buffer is provided below.

2. Equilibrate a solid support which is conjugated with nickel or cobalt with the equilibration buffer disclosed below. The poly-histidine tag specifically binds to the nickel and cobalt atoms on the solid support. Equilibration can be achieved by washing

the resin three times with a volume of the equilibration buffer equal to ten times the volume of the solid support. The solid support is readily available to persons of ordinary skill in the art.

3. Add the cell lysate to the solid support and
5 equilibrate in a vessel for a period of time.
Alternatively, the solid support can be packed within a protein chromatography column and the lysate may be flowed through the solid support.

4. Wash the solid support with the wash buffer
10 disclosed below.

5. Elute the MEK or MAPK protein from the solid support with an amount of elution buffer (provided below) that removes a significant portion of the protein from the solid support.

15

Sonication Buffer

50 mM sodium phosphate pH 8.0

0.3 M sodium chloride

10 mM β -mercaptoethanol

20 1% NP40

10 mM NaF

0.5 mM Pefablock

Equilibration Buffer

50 mM sodium phosphate pH 8.0
0.3 M sodium chloride
10 mM β -mercaptoethanol
1% NP40
5 10 mM NaF
1 mM Imidazol

Wash Buffer

50 mM sodium phosphate pH 8.0
10 0.3 M sodium chloride
10 mM β -mercaptoethanol
1% NP40
10 mM NaF
10 mM Imidazol

15

Elution Buffer

50 mM sodium phosphate pH 8.0
0.3 M sodium chloride
10 mM β -mercaptoethanol
20 1% NP40
10 mM NaF
10 - 500 mM Imidazol

**EXAMPLE 4: ASSAY MEASURING THE EFFECT OF
QUINAZOLINE-BASED COMPOUNDS ON THE GROWTH
OF CELLS EXPRESSING RAF**

The following assay measures growth rates for NIH-3T3 cells expressing RAF-1. The protocol for the assay is described in detail in PCT Publication WO9640116, filed June 5, 1996, by Tang et al., and entitled "Indolinone Compounds for the Treatment of Disease," incorporated herein by reference in its entirety, including any drawings.

Select compounds inhibited the growth rates of the cells overexpressing RAF as shown in Table 2.

TABLE 2

Compound	IC ₅₀ (μM) RAF/NIH3T3
A-1	0.16
A-7	1.7
A-9	5.9

EXAMPLE 5: ASSAY MEASURING THE EFFECT OF
 QUINAZOLINE-BASED COMPOUNDS ON THE GROWTH
 OF CELLS EXPRESSING RAS

The following assay measures growth rates for NIH-3T3 cells expressing RAS. The purpose of the assay is
5 to determine the effects of compounds on the growth of
NIH 3T3 cells over expressing H-Ras.

Materials

96-well flat bottom sterile plates
10 96-well round bottom sterile plates
sterile 25 mL or 100 mL reservoir
pipets, multi-channel pipetman
sterile pipet tips
sterile 15 mL and 50 mL tubes

15

Reagents

0.4% SRB in 1% acetic acid
10 mM Tris base
10% TCA
20 1% acetic acid
sterile DMSO (Sigma)
compound in DMSO (100 mM or less stock solution)
Trypsin-EDTA (GIBCO BRL)

25 Cell line:

3T3/H-Ras (NIH 3T3 clone 7 cells expressing genomic
fragment of oncogenic H-Ras).

The cells can be constructed using the following
protocol:

1. Subclone a gene fragment encoding Ras into a commercially available vector that will stably transfect NIH-3T3 cells. The fragment is from the genomic transforming allele of cHa-ras.

2. Transfect NIH-3T3 cells with the subcloned
5 vector by a calcium phosphate method. Select cells expressing the Ras construct in 2% serum in DMEM. Visible foci are observed after 2 weeks. Pool the transformed cells to generate a stably transformed cell line.

10

Growth medium:

2% calf serum/DMEM + 2 mM glutamine, Pen/Strep

Protocol:

15 Day 0: Cell Plating:

This part of assay is carried out in a laminar flow hood.

1. Trypsinize cells. Transfer 200 μ L of cell
20 suspension to 10 mL of isotone. Count cells with a Coulter Counter.

2. Dilute cells in growth medium to 60,000 cell/mL. Transfer 100 μ L of cells to each well in a 96-well flat bottom plate to give 6000 cells/well.

25 3. Use half of plate (4 rows) for each compound and quadruplicate wells for each compound concentration, and a set of 4 wells for medium control.

4. Gently shake plates to allow for uniform

attachment of the cells.

5. Incubate the plates at 37 °C in a 10% CO₂ incubator.

Day 1: Addition of Compound:

5 This part of assay is carried out in a laminar flow hood.

1. In a 96-well round bottom plate, add 120 µL of growth medium containing 2X final % DMSO found in
10 highest screening concentration of compound to columns 1 to 11. For example, if the highest concentration is 100 µL, and this is made from a 100 mM stock, 1X DMSO is 0.1%, so 2X DMSO is 0.2%. This plate is used to titrate out the compound, 4 rows per compound.

15 2. In a sterile 15 mL tube, make a 2X solution of the highest screening concentration of compound in growth medium plus 2X DMSO. 1 mL per cell line is needed. The starting concentration of the compound is usually 100 µM but this concentration may vary depending
20 upon the solubility of the compound.

3. Transfer 240 µL of the 2X starting compound solution to quadruplicate wells in column 12 of the 96-well round bottom plate. Do 1:2 serial dilutions across the plate from right to left by transferring 12 µL from
25 column 12 to column 11, column 11 to 10 and so on through column 2. Transfer 100 µL of compound dilutions, and 100 µL of medium in column 1, onto 100 µL

medium on cells in corresponding wells of 96-well flat bottom plate. Total volume per well should be 200 μ L.

4. Return the plate to the incubator and incubate for 3 days.

5 Day 4: Development of Assay

This part of assay is carried out on the bench.

1. Aspirate or pour off medium. Add 200 μ L cold 10% TCA to each well to fix cells. Incubate plate for at least 60 min. at 4 $^{\circ}$ C.

2. Discard TCA and rinse wells 5 times with tap water. Dry plates upside down on paper towels.

3. Stain cells with 100 μ L/well 0.4% SRB for 10 min.

4. Pour off SRB and rinse wells 5 times with 1% acetic acid. Dry plates completely upside down on paper towels.

5. Solubilize dye with 100 μ L/well 10 mM Tris base for 5-10 min. on shaker.

6. Read plates on Dynatech ELISA Plate Reader at 570 nm with reference at 630 nm.

Select compounds inhibited the growth rate of cells over-expressing RAS as illustrated in Table 3.

TABLE 3

Compound	IC ₅₀ (μ M) RAS/NIH3T3
A-1	0.85
A-7	>100
A-9	20.4
A-8	22.3
A-6	>100
A-22	0.4
A-23	0.6
A-28	6

EXAMPLE 6: ASSAY MEASURING EFFECT OF QUINAZOLINE-BASED COMPOUNDS ON GROWTH OF A549 CELLS

The following assay measures growth rates for A549 cells. The purpose of the assay is to determine the effects of compounds on the growth of A549 human lung carcinoma cells. A549 cells are readily accessible from commercial sources, such as ATCC (CCL185).

Materials:

- 96-well flat bottom sterile plates
- 96-well round bottom sterile plates
- sterile 25 mL or 100 mL reservoir
- pipets, multi-channel pipetman
- 5 sterile pipet tips
- sterile 15 mL and 50 mL tubes

Reagents:

- 0.4% SRB in 1% acetic acid
- 10 10mM Tris base
- 10% TCA
- 1% acetic acid
- sterile DMSO (Sigma)
- compound in DMSO (100 mM or less stock solution)
- 15 Trypsin-EDTA (GIBCO BRL)

Cell line and growth medium:

- A549 human lung carcinoma cells (ATCC CCL185)
- 10% fetal calf serum in Ham's F12-K
- 20

Protocol:

Day 0: Cell Plating:

This part of assay is carried out in a laminar flow hood.

25

1. Trypsinize cells. Transfer 200 μ L of cell suspension to 10 mL of isotone. Count cells with a Coulter Counter.

2. Dilute cells in growth medium to 20,000 cell/mL. Transfer 100 μ L of cells to each well in a 96-well flat bottom plate to give 2000 cells/well.

3. Use half of plate (4 rows) for each compound and quadruplicate wells for each compound concentration, and a set of 4 wells for medium control.

4. Gently shake plates to allow for uniform attachment of the cells.

5. Incubate the plates at 37°C in a 10% CO₂ incubator.

10

Day 1: Addition of Compound:

This part of assay is carried out in a laminar flow hood.

15 1. In a 96 well-round bottom plate, add 120 μ L of growth medium containing 2X final %DMSO found in highest screening concentration of compound to columns 1 to 11. For example, if the highest screening concentration is 100 μ M, and this is made from a 100mM stock, 1X DMSO is 0.1%, so 2X DMSO is 0.2%. This plate is used to titrate out the compound, 4 rows per compound.

20 2. In a sterile 15 mL tube, make a 2X solution of the highest screening concentration of compound in growth medium plus 2X DMSO. 1 mL per cell line is needed. The starting concentration of the compound is usually 100 μ M but this concentration may vary depending upon the solubility of the compound.

25 3. Transfer 240 μ L of the 2X starting compound

solution to quadruplicate wells in column 12 of the 96-well round bottom plate. Do 1:2 serial dilutions across the plate from right to left by transferring 120 μ L from column 12 to column 11, column 11 to 10 and so on through column 2. Transfer 100 μ L of compound dilutions, and 100 μ L of medium in column 1, onto 100 μ L medium on cells in corresponding wells of 96-well flat bottom plate. Total volume per well should be 200 μ L.

4. Return the plate to the incubator and incubate for 3 days.

10

Day 5: Development of Assay

This part of assay is carried out on the bench.

1. Aspirate or pour off medium. Add 200 μ L cold 10% TCA to each well to fix cells. Incubate plate for at least 60 min. at 4°C.

2. Discard TCA and rinse wells 5 times with tap water. Dry plates upside down on paper towels.

3. Stain cells with 100 μ L/well 0.4% SRB for 10 min.

4. Pour off SRB and rinse wells 5 times with 1% acetic acid. Dry plates completely upside down on paper towels.

5. Solubilize dye with 100 μ L/well 10 mM Tris base for 5-10 min. on shaker.

6. Read plates on Dynatech ELISA Plate Reader at 570 nm with reference at 630 nm.

Select compounds inhibited the growth rates of

A549 cells, as illustrated in Table 4.

TABLE 4

Compound	IC ₅₀ (μ M) A549
A-1	15.9
A-7	17.7
A-8	77.9
A-22	26
A-23	18
A-28	32

EXAMPLE 7: METHOD FOR MEASURING PHOSPHORYLATING
FUNCTION OF EGFR

EGF Receptor kinase activity (EGFR-NIH3T3 assay) in whole cells was measured as described in detail in PCT Publication WO9640116, filed June 5, 1996, by Tang et al., and entitled "Indolinone Compounds for the Treatment of Disease," incorporated herein by reference in its entirety, including any drawings.

IC₅₀ values were measured for quinazoline compounds in the EGFR ELISA assay and reported in Table 5:

TABLE 5

Compound	IC ₅₀ (μ M) A549
A-1	24.6
A-6	>100

A-7	>100
A-22	>100
A-23	17.2
A-28	75.1

5

EXAMPLE 8: METHOD FOR DETERMINING THE BIOLOGICAL
ACTIVITY OF RAF MODULATORS IN VIVO

Xenograft studies can be utilized to monitor the
effect of compounds of the invention upon the inhibition
of ovarian, melanoma, prostate, lung and mammary tumor
cells. The protocol for the assay is described in
detail in PCT Publication WO9640116, filed June 5, 1996,
by Tang et al., and entitled "Indolinone Compounds for
the Treatment of Disease," incorporated herein by
reference in its entirety, including any drawings.

The invention illustratively described herein may
be practiced in the absence of any element or elements,
limitation or limitations which is not specifically
disclosed herein. The terms and expressions which have
been employed are used as terms of description and not
of limitation, and there is no intention that in the use
of such terms and expressions of excluding any
equivalents of the features shown and described or
portions thereof, but it is recognized that various
modifications are possible within the scope of the
invention claimed. Thus, it should be understood that
although the present invention has been specifically

disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as
5 defined by the appended claims.

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The
10 molecular complexes and the methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes
15 therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be
20 made to the invention disclosed herein without departing from the scope and spirit of the invention.

All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All
25 patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising",
5 "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and
10 expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention
15 has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this
20 invention as defined by the appended claims.

In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any
25 individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being

bromine and chlorine are fully described.

Those references not previously incorporated herein by reference, including both patent and non-patent references, are expressly incorporated herein by reference for all purposes. Other embodiments are
5 within the following claims.

What is claimed is:

CLAIMS

1. A method of modulating the function of a serine/threonine protein kinase with a quinazoline-based compound substituted at the 5-position with an optionally substituted five-membered or six-membered aryl or heteroaryl ring, comprising the step of contacting cells expressing said serine/threonine protein kinase with said compound.

2. The method of claim 1, wherein said serine/threonine protein kinase is RAF.

3. A method of identifying compounds that modulate the function of serine/threonine protein kinase, comprising the following steps:

- (a) contacting cells expressing said serine/threonine protein kinase with said compound; and
- (b) monitoring an effect upon said cells.

4. The method of claim 3, wherein said effect is a change or an absence of a change in cell phenotype.

5. The method of claim 3, wherein said effect is a change or an absence of a change in cell proliferation.

6. The method of claim 3, wherein said effect is

a change or absence of a change in the catalytic activity of the said serine/threonine protein kinase.

7. The method of claim 3, wherein said effect is a change or absence of a change in the interaction
5 between said serine/threonine protein kinase with a natural binding partner, as described herein.

8. The method of claim 3, comprising the following steps:
10 (a) lysing said cells to render a lysate comprising serine/threonine protein kinase;
(b) adsorbing said serine/threonine protein kinase to an antibody;
(c) incubating said adsorbed serine/threonine
15 protein kinase with a substrate or substrates; and
(d) adsorbing said substrate or substrates to a solid support or antibody;
wherein said step of monitoring said effect on said cells comprises measuring the phosphate concentration of
20 said substrate or substrates.

9. The method of claim 3, wherein said serine/threonine protein kinase is RAF and comprises the following steps:
25 (a) lysing said cells to render a lysate comprising RAF;
(b) adsorbing said RAF to an antibody;
(c) incubating the adsorbed RAF with MEK and


MAPK; and

(d) adsorbing said MEK and MAPK to a solid support or antibody or antibodies;


wherein said step of measuring said effect on said cells comprises monitoring the phosphate concentration of said MEK and MAPK.

10. The method of claim 1, wherein said quinazoline-based compound has the formula set forth in structure I, II, or III:


(I)



(II)



(III)



wherein

(a) Z is oxygen, NX₁, or sulfur, where X₁ is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(b) n is 0, 1, 2, 3, or 4;

(c) A₁, A₂, A₃, A₄, A₅, and A₆ are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur;

(d) R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, and R₁₀ are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX₂X₃, where X₂ and X₃ are

independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(iv) halogen or trihalomethyl;

(v) a ketone of formula -CO-X₄,

where X₄ is selected from the group consisting of

hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl moieties;

(vi) a carboxylic acid of formula - $(X_5)_n$ -COOH or ester of formula - $(X_6)_n$ -COO- X_7 , where X_5 , X_6 , and X_7 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1;

(vii) an alcohol of formula $(X_8)_n$ -OH or an alkoxy moiety of formula - $(X_8)_n$ -O- X_9 , where X_8 and X_9 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl ring moieties and where n is 0 or 1, and where said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(viii) -NHCOR₁₀, where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aryl or heteroaryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(ix) -SO₂NX₁₁X₁₂, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(x) a five-membered or six-membered aryl or heteroaryl ring moiety optionally substituted

with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;

5 (g) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the quinazoline ring;

10 (h) R_{11} and R_{12} are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;


and

15 (i) Z' is carbon, oxygen, sulfur, or nitrogen and R_{13} and R_{14} taken together form a five-membered or six-membered heteroaryl ring with Z' as a ring member.


20 11. The method of claim 1, wherein said quinazoline-based compound has the formula set forth in structure I, II, or III:

100


(I)



(II)



(III)



wherein

(a) Z is oxygen, NX_1 , or sulfur, where X_1 is selected from the group consisting of hydrogen and saturated or unsaturated alkyl;

(b) n is 0, 1, or 2;

(c) A_1 , A_2 , A_3 , A_4 , A_5 , and A_6 are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur;

(d) R_1 and R_2 are independently selected from the group consisting of

- (i) hydrogen;
- (ii) saturated or unsaturated alkyl;
- (iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and
- (iv) halogen or trihalomethyl;
- (v) five-membered or six-membered aryl or heteroaryl ring moiety;

(e) R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of

- (i) hydrogen;
- (ii) saturated or unsaturated alkyl;
- (iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and
- (iv) halogen or trihalomethyl;
- (v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine;

(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety;

(f) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl

or heteroaryl ring comprises two carbon atoms of the quinazoline ring;



(g) R_{11} and R_{12} are independently selected from the group consisting of

(i) hydrogen; and

(ii) saturated or unsaturated alkyl; and

(h) Z' is nitrogen, oxygen, or sulfur and R_{13} and R_{14} taken together form a five-membered or six-membered heteroaryl ring moiety with Z' as a ring member, wherein said ring is optionally substituted with one, two, or three alkyl, halogen, trihalomethyl, carboxylate, and ester moieties.

12. The method of claim 1, wherein said quinazoline-based compound has the structure set forth in formula IV or V:



wherein


- (a) Z is oxygen or sulfur;
- (b) n is 0 or 1;
- (c) R_1 and R_2 are independently selected from the group consisting of
 - 5 (i) hydrogen; and
 - (ii) NX_1X_2 , where X_1 and X_2 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl;
 - (iii) benzyl;
- 10 (d) R_3 , R_4 , and R_5 are independently selected from the group consisting of
 - (i) hydrogen; and
 - (ii) saturated or unsaturated alkyl;
 - (iii) NX_3X_4 , where X_3 and X_4 are
- 15 independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl;
- (e) R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of
 - (i) hydrogen;
 - 20 (ii) saturated or unsaturated alkyl;
 - (iii) NX_5X_6 , where X_5 and X_6 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and
 - (iv) halogen or trihalomethyl;
 - 25 (v) $C(X_7)_3$, where X_7 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and
 - (vi) methoxy;

(f) R_{11} and R_{12} are hydrogen; and


(g) Z' is nitrogen and R_{13} and R_{14} taken together form a five-membered heteroaryl ring.

13. The method of claim 1, wherein said
5 quinazoline-based compound has a structure set forth in formula VI or VII:

(VI)



(VII)



wherein

10 (a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

(b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently selected from the group consisting of

15 (i) hydrogen;
(ii) saturated or unsaturated alkyl;
(iii) NX_4X_5 , where X_4 and X_5 are

independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

20 (iv) halogen;
(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and

iodine; and


(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.

5


14. The method of claim 1, wherein said quinazoline-based compound has a structure set forth in formula VIII or IX:

10

(VIII)



(IX)



wherein

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

15

(b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently selected from the group consisting of

- (i) hydrogen;
- (ii) saturated or unsaturated alkyl;
- (iii) NX_4X_5 , where X_4 and X_5 are

20

independently selected from the group consisting of


hydrogen and saturated or unsaturated alkyl; and

(iv) halogen;

(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and

5 (vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.

10 15. The method of claim 1, wherein said quinazoline-based compound has a structure set forth in formula X:



15 wherein

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

(b) R_3 , R_4 , R_5 , and R_6 are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and


(iv) halogen;

(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and


(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.

16. The method of claim 1, wherein said quinazoline-based compound is selected from the group consisting of:


A-1




A-2













A-3







A-4




108



109




and




- 5 17. A method of preventing or treating an abnormal condition in an organism, comprising the step of administering a quinazoline-based compound of formula I, II, or III to said organism:


(I)



(II)



(III)



wherein

(a) Z is oxygen, NX_1 , or sulfur, where X_1 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(b) n is 0, 1, 2, 3, or 4;

(c) A_1 , A_2 , A_3 , A_4 , A_5 , and A_6 are independently selected from the group consisting of carbon, nitrogen,

oxygen, and sulfur;

(d) $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9$, and R_{10} are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

5 (iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

10 (iv) halogen or trihalomethyl;

(v) a ketone of formula $-CO-X_4$, where X_4 is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl moieties;

15 (vi) a carboxylic acid of formula $-(X_5)_n-COOH$ or ester of formula $-(X_5)_n-COO-X_7$, where X_5, X_6 , and X_7 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1;

20 (vii) an alcohol of formula $(X_8)_n-OH$ or an alkoxy moiety of formula $-(X_8)_n-O-X_9$, where X_8 and X_9 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl ring moieties and where n is 0 or 1, and
25 where said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(viii) -NHCOX_{10} , where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aryl or heteroaryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(ix) $\text{-SO}_2\text{NX}_{11}\text{X}_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(x) a five-membered or six-membered aryl or heteroaryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;

(e) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the quinazoline ring;

(f) R_{11} and R_{12} are independently selected from the group consisting of


(i) hydrogen;

(ii) saturated or unsaturated alkyl;


(g) Z' is carbon, oxygen, sulfur, or nitrogen and R_{13} and R_{14} taken together form a five-membered or six-membered heteroaryl ring with Z' as a ring member.

18. The method of claim 17, wherein said quinazoline-based compound has a structure set forth in formula VI or VII:

(VI)



(VII)



5 where

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

10 (b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently selected from the group consisting of

- (i) hydrogen;
- (ii) saturated or unsaturated alkyl;
- (iii) NX_4X_5 , where X_4 and X_5 are

15 independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

- (iv) halogen;
- (v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and


20 (vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or

heteroaryl ring moiety.


19. The method of claim 17, wherein said quinazoline-based compound has a structure set forth in formula VIII or IX:

5

(VIII)



(IX)



where

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

10

(b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently selected from the group consisting of

- (i) hydrogen;
- (ii) saturated or unsaturated alkyl;
- (iii) NX_4X_5 , where X_4 and X_5 are

15

independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

- (iv) halogen;
- (v) $C(X_6)_3$, where X_6 is selected from the

20

group consisting of fluorine, chlorine, bromine, and

iodine; and


(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.

5

20. The method of claim 17, wherein said quinazoline-based compound has a structure set forth in formula X:

10

(X)



wherein

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

15

(b) R_3 , R_4 , R_5 , and R_6 are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_4X_5 , where X_4 and X_5 are

20

independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

(iv) halogen;

(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and

(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.

21. The method of claim 17, wherein said organism is a mammal.

22. The method of claim 17, wherein said abnormal condition is cancer or a fibrotic disorder.


23. The method of claim 22, wherein said abnormal condition is a cancer selected from the group consisting of lung cancer, ovarian cancer, breast cancer, brain cancer, intra-axial brain cancer, colon cancer, prostate cancer, Kaposi's sarcoma, melanoma, and glioma.

24. The method of claim 17, wherein said abnormal condition is associated with an aberration in a signal transduction pathway characterized by an interaction between a serine/threonine protein kinase and a natural binding partner.


25. The method of claim 24, wherein said serine/threonine protein kinase is RAF.

26. A quinazoline compound having a structure set forth in formula I, II, or III:


(I)



(II)



(III)



5

wherein

(i) Z is oxygen, NX_1 , or sulfur, where X_1 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

- (ii) n is 0, 1, 2, 3, or 4;
- (iii) A_1, A_2, A_3, A_4, A_5 , and A_6 are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur;
- (iv) R_1 and R_2 are independently selected from the group consisting of
- 5 (a) hydrogen;
- (b) saturated or unsaturated alkyl;
- (c) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of
- 10 hydrogen and saturated or unsaturated alkyl; and
- (d) halogen or trihalomethyl;
- (e) five-membered or six-membered aryl or heteroaryl ring moiety;
- (v) $R_3, R_4, R_5, R_6, R_7, R_8, R_9$, and R_{10} are
- 15 independently selected from the group consisting of:
- (a) hydrogen, provided that at least one of $R_3, R_4, R_5, R_6, R_7, R_8, R_9$, and R_{10} is a non-hydrogen moiety if R_2 is $-NH_2$;
- (b) saturated or unsaturated alkyl,
- 20 wherein said R_8 is not methyl when R_2 is $-NH_2$ and when $n = 1$;
- (c) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-
- 25 membered or six-membered aryl or heteroaryl ring moieties;
- (d) halogen or trihalomethyl, wherein said R_8 is not chlorine or fluorine when R_2 is -

NH₂ and when n = 1;

(e) a ketone of formula -CO-X₄,

where X₄ is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl moieties;

5 (f) a carboxylic acid of formula - (X₅)_n-COOH or ester of formula - (X₆)_n-COO-X₇, where X₅, X₆, and X₇ are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1;

10 (g) an alcohol of formula (X₈)_n-OH or an alkoxy moiety of formula - (X₈)_n-O-X₉, where X₈ and X₉ are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl ring moieties and where n is 0 or 1, and
15 wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(h) -NHCX₁₀, where X₁₀ is selected
20 from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aryl or heteroaryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;
25

(i) -SO₂NX₁₁X₁₂, where X₁₁ and X₁₂ are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl

ring moieties;

(j) a five-membered or six-membered aryl or heteroaryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;

(v) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the quinazoline ring;

(vi) R_{11} and R_{12} are independently selected from the group consisting of

(a) hydrogen;




(b) saturated or unsaturated alkyl;

and

(vii) Z' is carbon, oxygen, sulfur, or nitrogen and R_{13} and R_{14} taken together form a five-membered or six-membered heteroaryl ring with Z' as a ring member.

27. A quinazoline compound having the structure set forth in formula I, II, or III:

121



wherein

(a) Z is oxygen, NX_1 , or sulfur, where X_1 is selected from the group consisting of hydrogen and saturated or unsaturated alkyl;

(b) n is 0, 1, or 2;

(c) A_1 , A_2 , A_3 , A_4 , A_5 , and A_6 are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur;

(d) R_1 and R_2 are independently selected from the group consisting of

- 5 (i) hydrogen;
- (ii) saturated or unsaturated alkyl;
- (iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and
- 10 (iv) halogen or trihalomethyl;
- (v) five-membered or six-membered aryl or heteroaryl ring moiety;

(e) R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of:

- 15 (i) hydrogen, provided that at least one of R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} is a non-hydrogen moiety if R_2 is $-NH_2$;
- (ii) saturated or unsaturated alkyl, wherein said R_8 is not methyl when R_2 is $-NH_2$ and when n
- 20 $= 1$;
- (iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and
- (iv) halogen or trihalomethyl,
- 25 wherein said R_8 is not chlorine or fluorine when R_2 is $-NH_2$ and when $n = 1$;
- (v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine,

bromine, and iodine;

(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety;

5 (f) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the
10 quinazoline ring;

(g) R_{11} and R_{12} are independently selected from the group consisting of

(i) hydrogen; and


(ii) saturated or unsaturated alkyl; and

15 (h) Z' is nitrogen, oxygen, or sulfur and R_{13} and R_{14} taken together form a five-membered or six-membered heteroaryl ring moiety with Z' as a ring member, wherein said ring is optionally substituted with one, two, or three alkyl, halogen, trihalomethyl, carboxylate, and ester moieties.
20


28. A quinazoline compound having the structure set forth in formula IV or V:

124

(IV)



(V)



wherein

(a) Z is oxygen or sulfur;

(b) n is 0 or 1;

(c) R₁ and R₂ are independently selected from

the group consisting of

(i) hydrogen; and

(ii) NX₁X₂, where X₁ and X₂ are

independently selected from the group consisting of
hydrogen and saturated or unsaturated alkyl;

(iii) benzyl;

(d) R₃, R₄, and R₅ are independently selected

from the group consisting of

(i) hydrogen; and

(ii) saturated or unsaturated alkyl;

(iii) NX₃X₄, where X₃ and X₄ are

independently selected from the group consisting of

hydrogen and saturated or unsaturated alkyl;

(e) R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of:

5 (i) hydrogen, provided that at least one of R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} is a non-hydrogen moiety if R_2 is $-NH_2$;

(ii) saturated or unsaturated alkyl, wherein said R_8 is not methyl when R_2 is $-NH_2$ and when $n = 1$;

10 (iii) NX_5X_6 , where X_5 and X_6 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

(iv) halogen or trihalomethyl, wherein said R_8 is not chlorine or fluorine when R_2 is $-NH_2$ and when $n = 1$

15 (v) $C(X_7)_3$, where X_7 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and


(vi) methoxy;

(f) R_{11} and R_{12} are hydrogen; and


20 (g) Z' is nitrogen and R_{13} and R_{14} taken together form a five-membered heteroaryl ring.

29. A quinazoline compound having a structure set forth in formula VI or VII:

(VI)



(VII)



wherein

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

5 (b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently selected from the group consisting of

(i) hydrogen, provided that at least one of R_3 , R_4 , R_5 , R_6 , and R_7 is a non-hydrogen moiety if R_2 is $-NH_2$;

10 (ii) saturated or unsaturated alkyl, wherein said R_5 is not methyl when R_2 is $-NH_2$;

(iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

15 (iv) halogen, wherein said R_5 is not chlorine or fluorine when R_2 is $-NH_2$;

(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and


20 (vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or

heteroaryl ring moiety.


30. A quinazoline compound having a structure set forth in formula VIII or IX:

5

(VIII)



(IX)



wherein

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

10

(b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl;

(iii) NX_4X_5 , where X_4 and X_5 are

15

independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

(iv) halogen;


(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and

20

iodine; and

(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.

5 31. A quinazoline compound having a structure set forth in formula X:



wherein

10 (a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

 (b) R_3 , R_4 , R_5 , and R_6 are independently selected from the group consisting of

15 (i) hydrogen;

 (ii) saturated or unsaturated alkyl;

 (iii) NX_4X_5 , where X_4 and X_5 are

independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

20 (iv) halogen;

 (v) $C(X_6)_3$, where X_6 is selected from the

group consisting of fluorine, chlorine, bromine, and


iodine; and

(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety.


5

32. A quinazoline compound selected from the group consisting of:

A-3




A-6




10


A-8




A-10










A-11



A-12




130



33. A pharmaceutical composition comprising a quinazoline compound of any one of claims 26-32 or salt thereof, and a physiologically acceptable carrier or diluent.


34. A method for synthesizing a compound of claim 26, comprising the steps of:

(a) reacting a first reactant with a second reactant to yield said compound, wherein said first reactant has a structure of formula XI:




and wherein said second structure has a structure of formula (XII) or (XIII):

(XII)



(XIII)



wherein,

- (a) Z is oxygen or sulfur;
- (b) n is 0, 1, 2, 3, or 4;

(c) A_1 , A_2 , A_3 , A_4 , A_5 , and A_6 are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur;

(d) R_1 and R_2 are independently selected from the group consisting of

- 5 (i) hydrogen;
- (ii) saturated or unsaturated alkyl;
- (iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and
- 10 (iv) halogen or trihalomethyl;
- (v) five-membered or six-membered aryl or heteroaryl ring moiety;

(e) R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of:

- 15 (i) hydrogen, provided that at least one of R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} is a non-hydrogen moiety if R_2 is $-NH_2$;
- (ii) saturated or unsaturated alkyl, wherein said R_8 is not methyl when R_2 is $-NH_2$ and when n
- 20 $= 1$;
- (iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;
- 25 (iv) halogen or trihalomethyl, wherein said R_8 is not chlorine or fluorine when R_2 is $-NH_2$ and when $n = 1$;

(v) a ketone of formula $-\text{CO}-\text{X}_4$, where X_4 is selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl moieties;

5 (vi) a carboxylic acid of formula $-(\text{X}_5)_n-\text{COOH}$ or ester of formula $-(\text{X}_6)_n-\text{COO}-\text{X}_7$, where X_5 , X_6 , and X_7 and are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1;

10 (vii) an alcohol of formula $(\text{X}_8)_n-\text{OH}$ or an alkoxy moiety of formula $-(\text{X}_8)_n-\text{O}-\text{X}_9$, where X_8 and X_9 are independently selected from the group consisting of alkyl and five-membered or six-membered aryl or heteroaryl ring moieties and where n is 0 or 1, and wherein said ring moieties are optionally substituted
15 with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(viii) $-\text{NHCOX}_{10}$, where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aryl or heteroaryl ring
20 moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

25 (ix) $-\text{SO}_2\text{NX}_{11}\text{X}_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(x) a five-membered or six-membered aryl or heteroaryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;

5 (f) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the
10 quinazoline ring;

(g) R_{11} and R_{12} are independently selected from the group consisting of

(i) hydrogen;


(ii) saturated or unsaturated alkyl; and

15 (b) collecting a precipitate comprising said compound.



35. A method for synthesizing a compound of claim 29, comprising the steps of:

20 (a) reacting a first reactant with a second reactant yielding said compound, wherein said first reactant has a structure of formula XIV:

(XIV)



and wherein said second reactant has a structure of formula XV or XVI:



wherein,

5 (a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

(b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently selected from the group consisting of

10 (i) hydrogen, provided that at least one of R_3 , R_4 , R_5 , R_6 , and R_7 is a non-hydrogen moiety if R_2 is $-NH_2$;

(ii) saturated or unsaturated alkyl, wherein said R_5 is not methyl when R_2 is $-NH_2$;

15 (iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

(iv) halogen, wherein said R_5 is not chlorine or fluorine when R_2 is $-NH_2$;

20 (v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and

(vi) OX_7 , where X_7 is selected from the group consisting of hydrogen, saturated or unsaturated

136


alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety; and

(b) collecting a precipitate comprising said compound.

36. A method for synthesizing a compound of claim 28, comprising the steps of:


(a) reacting a first reactant with a second reactant yielding said compound, wherein said first reactant has a structure of formula XIV:

(XIV)



and wherein said second reactant has a structure of formula XVII or XIII:

(XVII)



(XIII)



wherein,

(a) R_1 and R_2 are independently selected from the group consisting of hydrogen and $-NH_2$, provided at least one of R_1 and R_2 is $-NH_2$;

(b) R_3 , R_4 , R_5 , R_6 , and R_7 are independently

selected from the group consisting of

(i) hydrogen, provided that at least one of R_3 , R_4 , R_5 , R_6 , and R_7 is a non-hydrogen moiety if R_2 is $-NH_2$;

(ii) saturated or unsaturated alkyl,
5 wherein said R_5 is not methyl when R_2 is $-NH_2$;

(iii) NX_4X_5 , where X_4 and X_5 are independently selected from the group consisting of hydrogen and saturated or unsaturated alkyl; and

(iv) halogen, wherein said R_5 is not
10 chlorine or fluorine when R_2 is $-NH_2$;

(v) $C(X_6)_3$, where X_6 is selected from the group consisting of fluorine, chlorine, bromine, and iodine; and

(vi) OX_7 , where X_7 is selected from the
15 group consisting of hydrogen, saturated or unsaturated alkyl, and a five-membered or six-membered aryl or heteroaryl ring moiety; and

(b) collecting a precipitate comprising said compound.

20

37. The method of any one of claims 34, 35, or 36 wherein said first reactant and said second reactant are mixed in one or more solvents selected from the group consisting of dimethyl sulfoxide, potassium tert-butoxide, and sodium hydride.

25


38. The method of claim 34, wherein said ZH moiety is isothiocyanate.

39. The method of claim 38, wherein said first reactant and said second reactant are mixed in dichloromethane.


40. A method for synthesizing a compound of claim 25, comprising the steps of

(a) reacting a first reactant with a second reactant yielding said compound, wherein said first reactant is guanidinium carbonate, and wherein said second reactant has the structure set forth in formula XIX or XX:

(XIX)



(XX)



wherein,

(a) A_1 , A_2 , A_3 , A_4 , A_5 , and A_6 are independently selected from the group consisting of carbon, nitrogen, oxygen, and sulfur;

(b) R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} are independently selected from the group consisting of:

(i) hydrogen, provided that at least one

of R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 , and R_{10} is a non-hydrogen moiety if R_2 is $-NH_2$;

(ii) saturated or unsaturated alkyl, wherein said R_8 is not methyl when R_2 is $-NH_2$ and when $n = 1$;

5 (iii) NX_2X_3 , where X_2 and X_3 are independently selected from the group consisting of hydrogen, saturated or unsaturated alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

10 (iv) halogen or trihalomethyl, wherein said R_8 is not chlorine or fluorine when R_2 is $-NH_2$ and when $n = 1$;

(v) a ketone of formula $-CO-X_4$, where X_4 is selected from the group consisting of hydrogen, 15 alkyl, and five-membered or six-membered aryl or heteroaryl moieties;

(vi) a carboxylic acid of formula $-(X_5)_n-COOH$ or ester of formula $-(X_6)_n-COO-X_7$, where X_5 , X_6 , and X_7 are independently selected from the group 20 consisting of alkyl and five-membered or six-membered aryl or heteroaryl moieties and where n is 0 or 1;

(vii) an alcohol of formula $(X_8)_n-OH$ or an alkoxy moiety of formula $-(X_8)_n-O-X_9$, where X_8 and X_9 are independently selected from the group consisting of 25 alkyl and five-membered or six-membered aryl or heteroaryl ring moieties and where n is 0 or 1, and wherein said ring moieties are optionally substituted with one or more substituents selected from the group

consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(viii) -NHCOX_{10} , where X_{10} is selected from the group consisting of alkyl, hydroxyl, and five-membered or six-membered aryl or heteroaryl ring moieties, wherein said ring moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester;

(ix) $\text{-SO}_2\text{NX}_{11}\text{X}_{12}$, where X_{11} and X_{12} are selected from the group consisting of hydrogen, alkyl, and five-membered or six-membered aryl or heteroaryl ring moieties;

(x) a five-membered or six-membered aryl or heteroaryl ring moiety optionally substituted with one or more substituents selected from the group consisting of alkyl, halogen, trihalomethyl, carboxylate, and ester moieties;

(f) any adjacent R_3 , R_4 , and R_5 or any adjacent R_6 , R_7 , R_8 , R_9 , and R_{10} are fused together to form a five-membered or six-membered aryl or heteroaryl ring moiety, wherein said five-membered or six-membered aryl or heteroaryl ring comprises two carbon atoms of the quinazoline ring;

(c) R_{11} and R_{12} are independently selected from the group consisting of

(i) hydrogen;

(ii) saturated or unsaturated alkyl; and

(b) collecting a precipitate comprising said

compound.

41. The method of claim 40, wherein said first reactant and said second reactant are mixed in N,N-dimethylacetamide.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/09060

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D239/84 C07D239/94 C07D239/95 C07D403/04 A61K31/505
C07D409/12 C07D405/12 C07D401/12 C07D403/12 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NEIL V. HARRIS: "ANTIFOLATE AND ANTIBACTERIAL ACTIVITIES OF 5-SUBSTITUTED 2,4-DIAMINOQUINAZOLINES." JOURNAL OF MEDICINAL CHEMISTRY., vol. 33, no. 1, 1990, pages 434-444, XP002074317 WASHINGTON US see page 434, paragraph CONCL. - page 438; tables 1-3	1, 10-14, 16-19, 21-24, 33
A	— — / —	26-30, 32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 August 1998

Date of mailing of the international search report

21/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/09060

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J.H.CHAN ET AL: "SELECTIVE INHIBITORS OF CANDIDA ALBICANS DIHYDROFOLATE REDUCTASE:ACTIVITY A.SELECTIVITY OF 5-ARYLTHIO-2,4-DIAMINOQUINAZOLINES." JOURNAL OF MEDICINAL CHEMISTRY., vol. 38, no. 18, 1995, pages 3608-3616, XP002074871 WASHINGTON US see page 3608 - page 3615; tables 5,7	26-29
Y		1,10-14, 16-19, 21-24,33
A		30,32
X	WO 94 18980 A (F.M.C.) 1 September 1994 see claims; examples 11,75-77; table 1	26-30
A	WO 93 20055 A (AGOURON) 14 October 1993 see the whole document	1,17-19, 21-26, 33-35
Y	CHEMICAL ABSTRACTS, vol. 124, no. 13, 1996 Columbus, Ohio, US; abstract no. 164193v, I.RAFI ET AL.: "CLINICAL PHARMACOKINETIC A. PHARMACODYNAMIC STUDIES WITH THE NONCLASSICAL ANTIFOLATE TYMIDYLATE SYNTHASE INHIBITOR 3,4-DIHYDRO-2-AMINO-6-METHYL-4-OXO-5-(4-PYRIDYLTHIO)QUINAZOLONE DIHYDROCHLORIDE(AG337)" page 24; XP002075175 see abstract & CLIN. CANCER RES., vol. 1, no. 11, 1995, pages 1275-1284, UK	1,10-14, 16-19, 21-24,33

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/09060

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 17-25
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 17-25
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/09060

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9418980 A	01-09-1994	AP 506 A	18-07-1996
		AP 507 A	18-07-1996
		AU 6298694 A	14-09-1994
		EP 0684824 A	06-12-1995
		MX 9401249 A	31-08-1994
		US 5534518 A	09-07-1996
		US 5616718 A	01-04-1997
		ZA 9401038 A	25-08-1994
WO 9320055 A	14-10-1993	US 5430148 A	04-07-1995
		AU 681075 B	21-08-1997
		AU 3966493 A	08-11-1993
		CA 2132514 A	14-10-1993
		EP 0637300 A	08-02-1995
		FI 944525 A	29-09-1994
		HU 68580 A	28-06-1995
		JP 7505395 T	15-06-1995
		NO 943629 A	29-09-1994
		NZ 251804 A	24-06-1997
		SG 46672 A	20-02-1998
		US 5707992 A	13-01-1998